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Abstract
Human umbilical cord blood (UCB) progenitor cells with high aldehyde dehydrogenase
activity (ALDHhi), can stimulate endogenous islet regeneration after transplantation into mice
with steptozotocin (STZ)-induced diabetes. However, UCB ALDHhi cell are extremely rare,
and expansion will be required to develop cell-mediated strategies to treat patients with
diabetes. To increase the number of progenitor cells available for clinical application, we
expanded ALDHhi UCB cells under clinically applicable, serum-free hematopoietic-restricted
conditions. Six day expansion resulted in a 15-fold increase in total cell number, and a 3-fold
increase in the number of HPC retaining high ALDH (ALDHhi HPC) activity. ALDHhi HPC
highly expressed primitive hematopoietic cell surface markers, and demonstrated
hematopoietic colony forming capacity in vitro. Culture-expanded ALDHhi HPC transplanted
STZ-induced mice demonstrated improved islet function, increased islet size, and
vascularization. Therefore, culture-expanded ALDHhi HPC represent a novel population for
the development of cellular therapies to promote islet regeneration.
Keywords: Aldehyde Dehydrogenase, Hematopoietic Progenitor Cells, Stem Cell Expansion,
Stem Cell Transplantation, Islet Regeneration, Islet Angiogenesis, Diabetes, Streptozotocintreated NOD/SCID mice.
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Introduction
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1.1 Human Pancreas
The human pancreas, located in the abdominal cavity behind the stomach, is composed of
exocrine cells (98%), and endocrine cells (1-2%). The exocrine acinar cells synthesize
enzymes such as trypsin, chymotrypsin, lipase, and amylase. The synthesized acinar cell
enzymes as well as bicarbonate secreted by pancreatic ductal epithelial cells, enter the
duodenum of the small intestine via pancreatic ducts, where these enzymes play an
important role in digestion.1 In contrast, endocrine cells are clustered throughout the
exocrine tissue in islets of Langerhans, and synthesize hormones that play an important
role in glucose homeostasis.
There are approximately 1 million islets in an adult human pancreas. The islets receive a
rich vascular supply from the splenic and mesenteric arteries, while the hormones
synthesized by the islets are secreted into capillaries collected by the portal vein. Pancreatic
islets consist of four major endocrine cell types: α-cells (35-40%), β-cells (50%), δ-cells
(10-15%), and pancreatic polypeptide (PP) cells, as well as more recently described
Epsilon cells.2 α-cells secrete glucagon, a 29 amino acid peptide hormone, when blood
glucose levels are low. Glucagon then binds to glucagon receptors on hepatocytes to
increase blood glucose levels, by stimulating the breakdown of glycogen into glucose, and
the synthesis of new glucose molecules from non-glucose fuel sources. Human β-cells of
the pancreas sense blood glucose levels via the GLUT1 and GLUT3 glucose transporters,
and secrete insulin, a 51 amino acid hormone, when blood glucose levels are high.2 Once
released insulin stimulates insulin responsive cells to uptake, store, and supress the
production of glucose. δ-cells of the pancreas secretes somatostatin that has potent
inhibitory effects on insulin, and glucagon release. PP-cells secrete the hormone PP, which
regulates both endocrine and exocrine secretions.3 Finally, Epsilon cells of the human
pancreas secrete Ghrelin, which has been shown to stimulate insulin secretion in the rat
pancreas, however its exact physiological role in the human islet is not known.4
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1.2 Diabetes Mellitus
The ancient Egyptian text, the Ebers Papryus written in 552 BC, described a disease that
caused patients to frequently urinate.5 In 234 BC the Greek physician Aretaeus, named this
disease diabetes. Diabetes mellitus, as it is now known, is a metabolic disease associated
with high blood glucose levels. According to the international diabetes federation 382
million people worldwide currently have diabetes. It is most prevalent in individuals above
65 years of age, and in people who live in urban areas. With a continued increase in the
aging population, and increased urbanization, it is predicted that 592 million people will
have diabetes in the year 2035. There are two main forms of diabetes, type 1 diabetes also
known as insulin-dependent diabetes mellitus or juvenile onset diabetes, and type 2
diabetes also known as insulin-independent diabetes mellitus or adult onset diabetes
(Figure 1.1).

1.2.1 Type 1 Diabetes
Type 1 diabetes is an auto-immune disorder where the body’s immune system mediates
the destructions of insulin secreting β cells of the pancreas.6 Currently, Type 1 diabetes
accounts for only 5-10% of total diabetic patients, and is the most predominant type of
diabetes in children. Recent epidemiological data suggest that, the incidence of type 1
diabetes is increasing worldwide at a rate of 3% a year.6
Histological analysis has shown that the pancreata of patients with type 1 diabetes have
lymphocytic infiltration of the pancreatic islets with destruction of insulin producing β
cells, resulting in an overall decrease in β cell mass. However, α cells, δ cells, and PP cells
of the islet are intact.7 The inflammatory infiltrate consists of CD8+ and CD4+ T cells, B
lymphocytes, macrophages, and natural killer (NK) cells.8
The non-obese diabetic (NOD) mouse model provides insight into the pathophysiology of
type 1 diabetes. NOD mice spontaneously develop autoimmune diabetes at around 10
weeks of age.9 Similar to human patients with type 1 diabetes, autoreactive CD4+ and CD8+
cells, macrophages, and lymphocytes are detected in the pancreatic infiltrate of NOD
mice.10 Studies using NOD mice have found that the process of β cell destruction begins
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when macrophages and dendritic cells present β cell antigens to naïve CD4+ T-cells, using
the major histocompatibility complex. CD4+ T-cells are then activated.11 In turn, activated
CD4+ T-cells activate CD8+ T-cells, which are directly responsible for mediating β cell
death.6 As a result of β cell death additional antigens are released, which permits antigen
presenting cells further access to self-antigens. Ongoing sampling of these autoantigens,
leads to the activation of additional auto-reactive T-cells, which results in the amplification
of the initial autoimmune response.6 Also, the inability of regulatory T-cells to inactivate
β cell specific autroreactive T-cells contributes to the pathogenesis of type 1 diabetes.12
Genetic and environmental factors both play a role in the etiology of type 1 diabetes. The
gene most associated with the risk for type 1 diabetes is the human leukocyte antigen
(HLA)-DR loci on chromosome 6.13 One in 40 individuals with a HLA-DR3 or HLA-DR4
at the HLA-DR loci will develop type 1 diabetes. Environmental factors such as diet, cow’s
milk, protein exposure, vitamin D deficiency, viral infections, drug toxins, and oxidative
stress are also thought to trigger type 1 diabetes in genetically predisposed individuals.14
Patients with type 1 diabetes present with weight loss, polyuria, and polydipsia.
Hyperglycemia, as a result of insulin deficiency, caused by a significant loss of β cell mass
explains these symptoms.6 Similar to patients with type 1 diabetes, patients with type 2
diabetes also demonstrate a loss of β cell function, and β cell mass, at the late stages of the
disease.

1.2.2 Type 2 Diabetes
Type 2 diabetes mellitus is a complex metabolic disorder characterized by hyperglycemia,
insulin resistance-a condition in which cells of the body fail to respond to insulin properlyand relative impairment in insulin secretion. Type 2 diabetes is the most common type of
diabetes, as it accounts for 90%-95% of diabetic patients.15 In the past decade, the
prevalence of type 2 diabetes has risen alarmingly primarily due to an increase in obesity
and a sedentary life style. Furthermore, it is worrisome that this disease which was
predominantly found in adults, is now increasingly seen in children and adolescents.15
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The development of insulin radioimmunoassays in the 1960’s led to the finding that plasma
insulin levels were often increased in type 2 diabetic patients, and therefore lead scientist
to believe that the failure to respond to insulin alone could explain the pathogenesis of type
2 diabetes.16 However, these studies did not measure insulin in the context of insulin
resistance. As a result, the role of β cell dysfunction in the pathogenesis of type 2 diabetes
was greatly overlooked.17 Research conducted in the past 15 years has shown that β cell
inadequacy is a fundamental part of type 2 diabetes. A longitudinal study on 48 Pima
Indians, showed that β cell dysfunction was prominent in those destined to progress to type
2 diabetes.18 Multiple measures of insulin sensitivity, and insulin secretion were carried
out on this very high risk population group. After an average of 5 years, 35% of these
subjects progressed from normal glucose tolerance, to impaired glucose tolerance, and then
to diabetes.15 Interestingly, the β cells of the subjects who eventually developed type 2
diabetes did not secrete enough insulin to overcome insulin resistance, indicating
diminished β cell function.19 Indeed, the insulin secretion of the subjects that developed
diabetes declined by 78%, while their insulin sensitivity only decreased by 14%.19 In a
matched group of subjects who did not develop diabetes, insulin sensitivity declined by
11%, but insulin secretion increased by 30%.19 In addition, data from the United Kingdom
Prospective Diabetes Study (UKPDS) that followed 3867 type 2 diabetes patients suggest
that β cell dysfunction commenced years before overt hyperglycemia developed.20
The diabetic milieu contributes to both β cell dysfunction, and insulin resistance in type 2
diabetic patients. Hyperglycemia impairs β cell function by increasing the rate of β cell
death, via the production of reactive oxygen species.21 An increase in circulating Nonesterfied fatty acids, is another characteristic of type 2 diabetic patients. Non-esterfied fatty
acids have been shown to reduce insulin mediated glucose uptake, and impair β cell
function both in vitro, and in vivo.16,22 The consumption of increased dietary fat triggers
the deposition of amyloid in pancreas.23 Amyloid plaques in islets are formed by the
aggregation of islet associated polypeptide (IAPP), and analysis of pancreas sections of
type 2 diabetic patients revealed that islets with large amyloid deposits often have fewer β
cells.24,25 When human IAPP is overexpressed in mice or rats, the result is worsening
diabetes associated with more amyloid deposition.25 It appears that the toxicity is exerted
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Figure 1.1 The mechanisms of Type 1 and Type 2 diabetes. Schematic representation
of the mechanisms underlying the pathogenesis of Type 1 and Type 2 diabetes. Type 1
diabetes is an autoimmune disorder where β cells are destroyed, leading to a reduced β cell
mass and reduced insulin secretion. Type 2 diabetes is a metabolic disease associated with
peripheral insulin resistance which reduces the uptake of glucose in tissues, and β cell
dysfunction which leads to impaired insulin secretion. Although glucose homeostasis is
impaired by varying mechanisms, both types of diabetes are associated with high blood
glucose levels.
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by a specific oligomeric components of the amyloid deposit that can damage cell
membranes, and increased lipid peroxidation.16
Genetic predispositions, and environmental factors such as diet, physical activity, and age
play a large role in the development of the disease.16 Furthermore, certain insults during
intrauterine fetal growth, such as placental insufficiency, have been associated with the
fetus developing type 2 diabetes later on in life.26 Since, the exact cause of type 2 diabetes
is not known, current therapeutic strategies aim to treat the symptoms of the disease.

1.3 Management of Diabetes
The symptoms associated with β cell dysfunction in both type 1 and type 2 diabetes are
treated using exogenous insulin. Furthermore, oral hypoglycemic agents are used to treat
the peripheral insulin resistance observed in type 2 diabetic patients.

1.3.1 Insulin Therapy
Fedrick Banting, Charles Best and John McLeod, demonstrated that intra-venous (i.v.)
injection of a pancreatic extract from dogs, could reduce blood glucose levels in diabetic
dogs.5 They called this extract “isletin”, which is now known as insulin.5 After this seminal
discovery, Banting, Best together with their new team member Collip attempted to increase
the supply of insulin for human use, by purifying insulin from the pancreas of cattle.5 The
pancreas extracts from cattle were first administered into Leonard Thompson, a 14 year
old boy with diabetes, on the 11th of January 1922.5 After the administration of insulin
injections Leonard’s condition dramatically improved. His blood glucose, and glucosuria
decreased, and his ketouria disappeared.27 Similar outcomes were archived when insulin
was administered to six other diabetic patients.5
Many advances to insulin have been made since its initial discovery in 1922. Eli Lily and
August Krogh worked independently to improve the extraction and purification of insulin
from animal sources. In the 1930’s protamine and zinc were added to animal insulin to
prolong its action.28 Then in 1978 the first human synthetic insulin was prepared by David
Goeddel and his colleagues at Genentech.5 The rapid and the short acting forms of synthetic
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insulin were marketed under the brand names Humulin R and Humulin NPH respectively.5
The discovery of insulin dramatically increased the life expectancy of diabetic patients.
Before the discovery of insulin the average life expectancy in diabetic patients was 6.1
years from diagnosis. Soon after insulin therapy became available to the general public the
average life expectancy of a diabetic patient increased to 18.2 years after diagnosis.
Now with advances such insulin pumps, and continuous blood glucose monitoring systems
both type 1 and type 2 diabetic patients can be managed more effectively.15 However, since
type 2 diabetic patients also demonstrate insulin resistance, additional pharmacological
agents are required to manage this disease. Even with modern insulin therapies and
pharmacological agents, the life expectancy of diabetic patients is reduced by 15 years.

1.3.2 Pharmacological Agents
Currently, patients presenting with type 2 diabetes symptoms are initially managed using
oral antidiabetic agents. These agents act through a variety of mechanisms to achieve
euglycemia. The American Diabetes Association, and the European Association for the
study of diabetes recommends a patient-centered approach with respect to medication
choices. When initiating pharmacological treatments, Metformin seems to be the drug of
choice, unless it is not tolerated by the patient.29 Metformin reduces blood glucose levels
in type 2 diabetic patients by reducing gluconeogenesis in the liver.30 Similar to Metformin,
Thiazolidinediones

also

reduce

gluconeogenesis

in

the

liver.31

Specifically,

Thiazolidinediones re-direct fat from the liver to subcutaneous adipose depots, thereby
improving insulin sensitivity in the liver. In contrast, Sulfonylureas lowers blood glucose
levels by stimulating insulin secretion from β cells.32 Type 2 diabetic patients also have
elevated triglyceride levels, which is a risk factor for cardiovascular disease. In addition to
lowering plasma blood glucose levels, the D2-dopamine agonist Bromocriptine reduces
plasma triglyceride and free fatty acid levels without increasing plasma insulin levels.33
However, it has been documented that approximately 25% of type 2 diabetic patients do
not respond sufficiently to the available therapies.29
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1.4 Diabetes Complications
Even with current insulin and drug therapy more than 90% of diabetic patients develop
long-term vascular complications.34 Diabetic vascular complications are grouped under
either microvascular or macrovascular disease. Microvascular complications arise due to
damages in small blood vessels, and includes: eye disease or retinopathy, kidney damage
or nephropathy, neural damage or neuropathy.35 The major macrovascular complications
include: accelerated cardiovascular disease resulting in myocardial infarction, and
cerebrovascular disease manifesting as strokes.35 The chronic elevation in blood glucose
levels is suggested to give rise to vascular complications by either damaging the cells of
the affected organs, or damaging the blood vessels that supply the affected organs. The
progression of these complications can be slowed but not stopped with aggressive
management of glycemia and blood pressure, laser therapy for advanced retinopathy, and
the administration of an angiotensin converting enzyme inhibitor or angiotensin receptor
II blocker for nephropathy.35 Thus, to prevent the morbidities associated with these
complications curative therapies that re-establish a functional β cell mass are currently
under intense investigation.36

1.5 Whole Pancreas Transplantation
Transplantation of cadaveric pancreata is performed in patients with type 1 diabetes, type
2 diabetes, and those who have undergone a total pancreatectomy.37 The first pancreas
transplant was performed in 1966 by William Kelly and Richard Lihelli at the University
of Minesota, USA.38 Since then, >27,000 pancreas transplants have been performed in the
United States of America.37 Over the years pancreas transplants have evolved from
experimental procedures to the standard of care for patients with severe diabetes mellitus
and uremia.37 Pancreas transplants are performed on three major categories of patients: 1)
patients with uremia who undergo simultaneous pancreas and kidney transplants, 2)
patients who are posturemic who undergo a pancreas transplant after a kidney transplant,
3) patients with brittle diabetes without uremia who undergo a pancreas transplant alone.37
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Overall the average graft survival, defined by insulin independence, was >96% 1 year post
transplant, and > 80% at 5 years.39 The time it takes to lose 50% of graft function ranges
from 7-14 years. Furthermore, a successful pancreas transplant seem to be a lot more
effective than intensive insulin therapy at lowering levels of HBA1c.40,41 Even 10 years
after transplantation, a successful pancreas transplant can preserve insulin secretion and
provide good glycemic control.

1.6 Islet Cell Transplantation
Islet cell transplantation is an alternate strategy that can be used to re-establish functional
β cell mass in severely diabetic patients. This procedure is gaining popularity, because of
the relatively low perioperative risks associated with islet cell transplantation when
compared to pancreas transplantation.42 The first attempt at islet transplantation was made
by Watson-Williams and Harsant in 1893, when they transplanted minced sheep’s pancreas
into the subcutaneous tissue of young boy with ketoacidosis.43 After the discovery of
insulin the interest in islet transplantation dwindled, but was renewed in 1972 when Drs.
Ballinger and Lacey demonstrated a method for isolating intact islets of Langerhans from
rodents that retained function after transplantation into a rodent model of diabetes.44
Twenty years later Scharp et al.45 was able use the islet transplantation methodology to
achieve insulin independence in a human diabetic patient for nearly 1 month. Further
advances and experimentation contributed to the development of the Edmonton protocol
in the year 2000. In this procedure, islets were procured from multiple (2-4) deceased
donors, purified, and then infused percutaneously into the portal vein of the recipient.
Furthermore, this is the first protocol that did not use steroid-based immunosuppressant
therapy due to its toxic effect on β cells. One-hundred percent of the recipients achieved
insulin independence after one year of transplantation, and none experienced severe
hypoglycemic episodes.46 However, continued autoimmune destruction of donor islets, the
need for life-long immunosuppressant therapy, and the critical shortage of donor pancreata
limits the use of this procedures.36
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1.7 Stem Cells
Due to the limitation of current β cell replacement therapies, methods of utilizing stem cells
to establish functional β cells for transplantation are being studied. Stem cells play an
important role in the development and regeneration of tissue and organ systems.47 These
cells have two distinguishing features, the ability to self-renew through cell division, and
the ability to differentiate into multiple cell types with specialized function.48 There are
three main types of stem cells: (1) Embryonic stem cells (ESC), (2) induced pluripotent
stem cells (iPSC), (3) adult stem cells (Figure 1.2).

1.7.1 Embryonic Stem Cells
ESC are derived from the inner-cell mass of 4-5 day old mouse or human blastocyst. These
cells are termed pluripotent, thereby have the ability to give rise to any of the 3 germ layers,
ectoderm, mesoderm, and endoderm.49 Martin Evans was the first to isolate and culture
mouse embryonic stem cells (mESC).50 To maintain pluripotency in vitro, Evans cultured
mESC on a feeder layer of division incompetent mouse fibroblast (MEF). Seventeen years
later the first human embryonic stem cells (hESC) was established, by Jamie Thompson.51
Similar to mESC, hESC were maintained in vitro by embryonic fibroblast feeder cells. The
establishment of hESC provide exciting prospects for cellular therapies. Currently,
researchers are attempting to differentiate human hESC into cell types of a wide range cell
lineages, to treat diseases associated will cellular deficiency.49

1.7.2 Induced Pluripotent Stem Cells
Induced pluripotent stem cell (iPSC) has flourished, as a result of the controversies
surrounding hESC research. iPSC were first generated by Shinya Yamanaka in 2007, by
expressing the transcription factors Oct4, Sox2, KLF4, and c-myc through retroviral
transduction in human skin fibroblasts.52 Similar to hESC, iPSC are pluripotent, and
thereby have the ability to differentiate into cells of all three germ layers of the body. iPSC
are currently used as tools for drug development, and modeling diseases. However,
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transduction using retroviruses may cause insertion mutagenesis, and subsequent adverse
effects such as cancer.53 Therefore, researchers are currently attempting to generate
retroviral free induction methods in order to generate iPSC that can be used in
transplantation medicine.54–58

1.7.3 Adult Stem Cells
Currently, there are few therapies using hESC or iPSC despite the promise that these cells
offer. This is due to difficulties of directing the production of a functional effector cells,
and their potential for teratoma forming capacity. In contrast, adult stem cells are safely
used in the clinic for a number of medical procedures including bone marrow (BM)
transplantation to treat hematological malignancies.
Adult stem cells, also known as somatic stem cells, are undifferentiated cells found among
differentiated cells within an organ. These cells are usually considered multipotent, since
they have the ability to differentiate into mature cells of a particular lineage, or germ layer.
The physiological role of adult stem cells is organ maintenance and repair, by replenishing
damaged or dying cells, so that organ function is maintained. Adult stem cells have been
identified in almost every organ in the human body including: the brain, BM, umbilical
cord blood (UCB), blood vessels, skeletal muscle, skin, gastro intestinal tract, liver, ovarian
epithelium, and testes. Of these many types of adult stem cells, hematopoietic stem cells
(HSC) which are derived from adult BM or UCB are extremely well characterized.

1.7.3.1 Hematopoietic Stem Cells
HSC demonstrate the ability to self-renew, and differentiate into specialized blood cells of
both the myeloid and lymphoid lineages. The initial evidence for the existence of HSC
came in the atomic era. It was found that the lethal consequences of radiation was due to
BM failure, and that this condition could be rescued following injection of spleen or BM
cells from unirradiated donors.59 The study of HSC moved from observational to functional
when landmark by Till and McCulloch showed that the regenerative potential of HSC could
be assayed using clonal in vivo repopulation assays, thus establishing the existence of a
multipotential HSC.60 Xenotransplantation assays were used to functionally characterize
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Figure 1.2 Differentiation Potential of Stem Cells. Schematic of the differentiation
potential of embryonic stem cells stem (ES) cells, induced pluripotent stem (iPS) cells, and
adult stem cells. ES cells, iPS cells, and adult stem cells all possess the ability to self-renew,
and differentiate. However, ES and iPS cells are pluripotent thereby can differentiate into
cells of all three germ layers. Whereas, adult stem cell such as hematopoietic stem cells
(HSC) are germ-layer specific in their differentiative ability.
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human HSC, and still remain the gold standard. The multipotency of HSC was
demonstrated by the ability of human HSC to repopulate the myeloid and lymphoid
compartment of the BM of an irradiated immunodeficient mouse.47,61 The self-renewal
potential of human HSC has been demonstrated by the ability of a single HSC to repopulate
the BM of a primary host, and give rise to other HSC that can reconstitute all blood lineages
in secondary hosts.47 In contrast, the most immediate progeny of HSC, hematopoietic
progenitor cells (HPC), loose their capacity for self-renewal, and therefore were unable to
reconstitute the BM of a secondary host.47,61
Cell surface molecules expression as HSC mature during hematopoiesis is a highly
regulated, and conserved process (Figure 1.3).62 For instance, early HSC and HPC express
the cell surface antigens CD34 CD133 and do not express CD38.63 Whereas, the more
lineage committed cells such as: myeloid progenitors, early thymic progenitors, and B/NK
cell progenitors do not express CD133, and express both CD34 and CD38. Finally, the
mature effector cells of the lymphoid, and myeloid lineage express lineage specific
markers, but do not express CD34 or CD38.61 Fluorescent monoclonal antibodies (CD34,
CD38, and CD133), and fluorescence activated cell sorting (FACs) can be used to separate
HSC and HPC populations (HSC/HPC) from more mature lineage committed cells (Lin+).
However, considerable controversy exists regarding the expression of CD34 on true HSC.
Bhatia et al.64 demonstrated that CD34-/CD38- cells isolated from UCB depleted of mature
lineage committed cells (Lin-) were functionally distinct from UCB Lin-/CD34+ HSC/HPC,
and these cells had the ability to initiate multilineage hematopoiesis in non-obese diabetic
severe combined immunodeficient (NOD/SCID) mice. It has also been reported that, UCB
Lin-/CD34- cells can generate CD34+ cells once transplanted into NOD/SCID mice.65 A
recent study showed that, Lin-/CD34-/CD38-/CD93+ UCB cells initiated multilineage
hematopoietic engraftment in both primary, and secondary hosts.66 Lin-/CD34-/CD38/CD93+ UCB cells were highly quiescent, compared to Lin-/CD34+/CD38- cells.
Furthermore, the progeny of Lin-/CD34-/CD38-/CD93+ cells, were more efficient at
engrafting to a secondary host, compared to the progeny of Lin-/CD34+/CD38- progenitor
cells. Suggesting that, Lin-/CD34-/CD38-/CD93+ cells are more primitive than Lin/CD34+/CD38- cells.
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Alternatively, HSC/HPC can be isolated according to stem cell function, rather than
phenotype. In order to facilitate the daily production of approximately one trillion (1012)
blood cells in the human body, the HSC/HPC pool must be maintained throughout the life
of the organism.61 Thus, enzymes such as aldehyde dehydrogenase (ALDH) that protects
against reactive aldehydes, and reactive oxygen species (ROS) are highly expressed in
HSC/HPC.67 In contrast, more mature blood effector cells have low ALDH activity (Figure
1.3). There are 19 structurally related ALDH isoforms in humans, and 20 ALDH isoforms
have been described in mice.68 Out of these isoforms ALDH1A1 is the most abundantly
expressed in HSC/HPC, but ALDHA1 knockout did not adversely affect HSC/HPC
function.69 Interestingly, ALDH1A1 knockout was associated with an increase in
ALDH3A1 in the HSC/HPC pool, suggesting this enzyme compensates for the loss of
ALDH1A1. The HSC/HPC pool in mice deficient in both ALDH1A1 and ALDH3A1, have
an increased ROS level, and are more sensitive to DNA damage. As a result, ALDH1A1
and ALDH3A1 deficient mice have reduced HSC/HPC cell numbers. In addition,
ALDH1A1 and ALDH3A1 deficient mice had deficiencies in B cell development. Thus,
this study illustrates that ALDH plays an important role in B cell development and
HSC/HPC survival.
In addition, ALDH1A1 is a critical enzyme in the biosynthesis of retinoic acid (RA), the
active metabolite of vitamin A (retinol).68 ALDHA1 catalyzes the oxidation of
retinaldehyde to retinoic acid, the final step in this process.70 RA, is a non-peptidic
lipophilic morphagen that enters the nucleus, and binds to the heterodimer formed by the
RA receptor (RAR) and the retinoid-x-receptor (RXR) to drive the transcription of target
genes.70 Human HSC/HPC are intrinsically programmed to undergo differentiation in
response to RA, since HSC/HPC highly express ALDHA1 and RARα. Human BM stromal
cells highly express CYP26 enzymes inactivates retinoids, and thereby maintains an
environment low in retinoids in the human BM. Culturing HSC/HPC ex vivo both in the
presence and absence of retinoic acid resulted HSC/HPC differentiation.70,71 Furthermore,
blocking the RAR receptor or ALDHA1 during ex vivo culture prevented HSC/HPC
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Figure 1.3 Adult Human hematopoietic hierarchy. Schematic representation of the
phenotypic markers expressed by hematopoietic stem/progenitor cells (HSC/HPC) and
mature blood cells (adapted from Doulatov et al.61) The expression of cell surface
molecules as HSC mature during hematopoiesis is a highly regulated process. Therefore,
cell surface markers can be used to separate more primitive HSC/HPC cells from more
mature lineage committed blood cells. Alternatively, HSC/HPC can be isolated according
to stem cell function via relative aldehyde dehydrogenase (ALDH) activity. HSC/HPC
have high ALDH activity, whereas more committed cells have low ALDH activity.
Myeloid progenitor (CMP), Lymphoid progenitor (CLP), T cell progenitor (CTP), B cell
progenitor (CBP), NK cell progenitor (NKP), granulocyte/macrophage progenitor (GMP),
megakaryocytic/erythroid progenitor (MEP).
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differentiation, and promoted HSC/HPC self-renewal.70,71 These studies suggest that,
retinoids play an important role in mediating key aspects of HSC self-renewal and
differentiation.
The fluorescent substrate for ALDH, BODIPY aminoacetaldehyde developed by Storms
et al.,72 and now marketed as Aldeflour™ by Stem Cell Technologies™ can be used to
detect relative ALDH activity. Aldeflour™ is a aminoacetadehyde moiety conjugated to a
BODIPY (4,4-difluoro-5,7-dimethyl-4-bora-3a,4adiaza-5-proprionic acid) flourochrome.
Once the lipophilic Aldeflour™ substrate enters the cells it is converted to an acetaldehyde
anion by ALDH. Under pharmacological inhibition of ABC transporters with the
Aldeflour™ buffer, cells with high ALDH activity retain a higher amount of Aldeflour™
compared to cells with low ALDH activity. Thereby, cells with high ALDH activity will
be brighter compared to cells with low ALDH activity, a property that enables the FACS
purification of these two populations

72,73

. The integrity and function of the cell are not

compromised by this procedure since upon removal of the Aldeflour™ buffer the ABC
transporter becomes reactivated and Aldeflour™ is pumped out of the cell returning the
cell to its original state, thus the isolated cells can be used for various downstream
applications.
Hess et al.,73 showed that, UCB progenitor cells with high ALDH (ALDHhi) activity
isolated from Lin- UCB have enhanced in vitro colonergic progenitor activity, and highly
co-express primitive hematopoietic cell phenotypes compared to UCB cells with low
ALDH (ALDHlo) activity. Furthermore, transplantation of Lin-/ALDHhi UCB progenitor
cells into NOD/SCID and NOD/SCID β2 microglobulin (β2M) null mice resulted in
multilineage human cell engraftment in hematopoietic tissues, while Lin-/ALDHlo UCB
cells were devoid of repopulation ability.74 Further dissection of the Lin-/ALDHhi UCB
progenitor population by using the cell surface molecule CD133 showed that, Lin/ALDHhi/CD133+ progenitor cells are significantly enriched for in vivo repopulating ability
compared to Lin-/ALDHhi/CD133- progenitor cells. Limiting dilution analysis
demonstrated that, Lin-/ALDHhi/CD133+ cells have a 10-fold increase in the frequency of
NOD/SCID repopulating cells (also known as SCID repopulating cells, SRC) compared
with Lin-/CD133+ cells. Furthermore, the hematopoietic and non-hematopoietic progeny
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of ALDHhi UCB trafficked efficiently to various organs including the pancreas after being
transplanted into glucuronidase (GUSB)-deficient NOD/SCID/mucopolysaccharidosis
type VII mice (MPSVII) mice. Therefore, Aldeflour™ can be used to isolate HSC/HPC.

1.7.3.2 Ex vivo Expansion of Hematopoietic Stem and Progenitor
Cells
The widespread initiatives to HLA-phenotype and cryopreserve human UCB in North
America and Europe, has ensured that UCB represents a readily available source of
HSC/HPC for cell therapy applications. However, the low number of HSC/HPC found in
UCB limits the widespread therapeutic application of transplanted UCB-derived HSC/HPC
in humans.75,76 Therefore, ex vivo expansion of HSC/HPC is one of the ways which the
number of UCB can be increased for cellular therapies.
The last two decades, researchers have established protocols aimed at the ex vivo expansion
of HSC/HPC for clinical application.75 Under serum free conditions, hematopoietic
cytokines are necessary for amplification HSC/HPC ex vivo.77,78 These signaling
molecules, are produced by stromal cells in the bone marrow, and induce the proliferation
of hematopoietic cells at various stages of development.76 The rapid discovery of new
hematopoietic growth factor’s and their receptors enabled researchers to find cytokines that
amplified HSC/HPC in culture.76 Initially HSC/HPC expansion was supported by
hematopoietic cytokines and serum. Since, serum is a potential source of bacterial,
mycoplasmas, and viral contaminants, many investigators attempted to develop serum free
conditions to expand HSC for clinical application.79 Through systematic analysis it was
found that stem cell factor (SCF), fms-related tyrosine kinase 3 ligand (FLT-3L), and
thrombopoietin (TPO) were essential cytokines for the expansion of primitive progenitor
cells in serum-free culture.77,78 In contrast, the addition of other cytokines such as:
interleukin-3 (IL-3), granulocyte colony stimulating factor (G-CSF), erythropoietin (EPO)
and macrophage colony-stimulating factor (M-CSF) supports the expansion of more
mature hematopoietic cells, instead of primitive HSC/HPC.80,81 Furthermore, research has
also established that the selection of a purified starting cell population is a key aspect in ex
vivo expansion protocols. ALDHhi, CD34+/CD38-, CD34+/CD133+ progenitor cells
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demonstrate a greater expansion potential than their more heterogeneous cell populations
containing mature cell counterparts.82–88 At the single cell level, multipotent progenitor
cells can give rise to 70×106 nucleated cells, and more than 90,000 CD34+ progenitor cells,
whereas mature erythroid progenitors can only produce 9×106 nucleated cells and no more
than 5,000 CD34+ progenitor cells.89 Currently, researchers are attempting to improve ex
vivo expansion technologies to increase the number of HSC/HPC available for cellular
therapies.85,90–102

1.8 Stem Cell Therapies for Diabetes
There are two major initiatives in the stem cell biology field to correct the loss of β cell
mass in both type 1, and type 2 diabetic patients: (1) generating β cells ex vivo, by utilizing
pluripotent stem cells; (2) stimulating the regeneration of β cells in the pancreas using adult
stem cells.36

1.8.1 β Cell Replacement
1.8.1.1 Derivation of β cells from ESC
A number different groups are attempting to differentiate ESC’s and iPSC’s into functional
β cells, to provide an unlimited source of β cells for replacement therapy in diabetic
patients.36 In order to generate glucose responsive pancreatic β cells from hESC, critical
signals that regulate endocrine pancreas development needs to be successfully
recapitulated in vitro. During normal development human epiblast cells first differentiate
into definite endoderm during gastrulation. Culturing hESC in Wnt3a and activinA leads
to cultures that contain 80% definitive endodermal cells.103,104 Attempts to efficiently
produce β cells from the definitive endoderm has not been as fruitful. In 2005 Novocell
(now Viacyte) developed a complex multi-step protocol to generate insulin-producing β
cells. However, only 7.3% of the cells generated using this protocol were positive for
insulin.105 By making modification to the Viacyte protocol Nostro et al.106 was able to
increase the number of insulin-producing cells to 25%. In both these protocols the insulin
producing cells were polyhormonal, and were not glucose responsive. Alternatively, Kroon
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et al.107 differentiated hESC into pancreatic-endocrine progenitor like cells in culture, and
subsequently transplanted these progenitor cells into streptozotocin induced (STZ)-diabetic
mice. Following transplantation, the endocrine progenitor-like cells matured into various
cell types, including functional β cells that normalized the blood glucose levels of these
diabetic mice. Although, these results were very encouraging, the composition,
organization, and mass of the resulting cellular structure from progenitor cell
differentiation in vivo was highly unpredictable.108 Furthermore, signals that stimulate
endocrine progenitor cells to differentiate into fully functional β cells remain unknown.108
Thus, the inability to differentiate hESC into functional β cells in culture, coupled with
ethical concerns and tumorigenicity of hESC-derived β cells, has prevented the use of
hESC-derived β cells in a clinical setting.

1.8.1.2 Derivation of β cells from iPSC
Similarly, iPSC can be used as a non-embryonic source for the derivation of β-like cells.
Murine iPSC–derived β-like cells have the capacity to normalize hyperglycemia in both a
type 1 and type 2 diabetic mouse models.109 Furthermore, iPSCs derived from the epiblast
of non-obese diabetic (NOD) mice differentiated into insulin-producing cells that
expressed diverse pancreatic β cell markers, and normalized hyperglycemia upon
transplantation into diabetic mice.110 In another study, human iPSCs derived from dermal
fibroblasts of patients with type 1 diabetes, were differentiated into cells that expressed
insulin, somatostatin, and glucagon in vitro.111 Interestingly, these cells were able to
produce insulin in response to glucose.111 Thus, iPSCs may be an appropriate choice for
generating autologous β cells, however like hESC, the clinical utility of iPSC is hampered
by incomplete maturation of differentiated cells, chromosomal aberrations, and enhanced
tumorigenic potential.112 Due to these limitations, strategies that stimulate endogenous islet
regeneration in situ are also under intense investigation.

1.8.2 Endogenous Islet Regeneration Therapies
The β cell mass in adult humans is maintained at a constant level with very low cellular
turnover.113 Interestingly, drastic increases in β cell mass have been observed in response
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to the increase in metabolic demand during pregnancy and obesity.114–116 Studies in mice
have attempted to elucidate the mechanism that induces β cells to re-enter the cell cycle.
Factors such as epidermal growth factor (EGF), insulin-like growth factor 1 (IGF1), human
growth hormone, prolactin, as well as glucose have been shown to stimulate β cell
proliferation in the mouse.117 In Hess and collegues118

initial publication on islet

regeneration, they showed that transplanted murine BM progenitor cells reduced
hyperglycemia in STZ-induced NOD/SICD (STZ-NOD/SCID) diabetic mice.118
Transplanted BM progenitor cells engrafted in the ductal and islet regions of the damaged
pancreas, but did not differentiate into insulin producing cells. Instead, BM progenitor cells
stimulated β cell proliferation, and enhanced insulin production in recipient-derived islets
via undetermined mechanisms.118 In order for endogenous islet regeneration to be a feasible
strategy, the signal receiving cells within the pancreas, and the mechanism by which
transplanted cells stimulate β cell expansion needs to be identified.

1.8.2.1 The Medalist Study
The medalist study followed 411 type 1 diabetic patients with disease duration of more
than 50 years.34 The majority (63.4%) of the medalist had c-peptide levels in the minimal,
and sustained range.34 Furthermore, their c-peptide release doubled during a mixed meal
tolerance test.34 Histological analysis of pancreas sections, from the patients that died
during the study showed the presence of insulin+ proliferating β cells.34 The data presented
in this study clearly supports that, residual functional β cells can remain in type 1 diabetic
patients with long standing diabetes. Thus, the amelioration of autoimmune destruction of
β cells, together with stimulating the regeneration of endogenous β cells, may represent a
feasible approach to improve endogenous insulin production in patients with type 1
diabetes. In order to develop better therapies to stimulate islet regeneration, the activation
of endogenous regenerative mechanisms within the pancreas must be understood.
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1.8.2.2 Mechanisms of Endogenous Islet Regeneration
The mechanisms by which new β cells arise in the post-natal pancreas is highly
controversial, and is still under intense research (Figure 1.4). To investigate the origin of
adult β cells, Dor et al.119 performed a pioneering lineage tracing experiment. These
researchers defined mature β cell as post-natal cells transcribing the insulin gene, and used
a pulse-chase lineage tracing approach to distinguish stem-cell derived β cells, from the
progeny of pre-existing β cells. Firstly, pre-existing mouse β cells were heritably labelled
with tamoxifen-inducible Cre transgene, rat insulin promoter (RIP)-CreER, and a human
alkaline phosphatase reporter (HAP, the pulse). Then the labelled cells (HPAP+) were
tracked over a period of time or after injury, during which cellular turnover occurred (the
chase). Using this approach, the cells generated from pre-exiting β cells are labelled, but
new β cells derived from any other cells, including stem cells will not be labelled. Thus, if
new islets are derived entirely from stem cells, these islets would not contain any labeled
β cells. If stem cells replenish β cells within existing islets, the frequency of labelled β cells
would gradually decrease. However, if new β cells are derived from pre-existing β cells the
frequency of labelled β cell within an islet would remain constant. Interestingly, over time
and after injury the total number of β cell increased, but the frequency of labelled β cells
remained constant.119 Thus, it was concluded that β cell expansion was primarily driven by
the division of already differentiated cells.
However, Dor et al.119’s definition of a mature β cell has been questioned by the recent
identification of a rare population of insulin expressing cells in the murine and human
pancreas that have progenitor like characteristics.120,121 These cell referred to as pancreasderived multipotent progenitor (PMP) cells, are able to form colonies in vitro and
differentiate into all hormone producing cells in the endocrine pancreas. Furthermore,
transplantation of both murine and human PMPs improved hyperglycemia in STZ-diabetic
mice.120,121 Thus, it is possible that these insulin+ precursors also contributed to the increase
in the number of β cells observed by Dor et al.119 Further research is required to delineate
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the relative contributions of mature β cells and β cell precursors during β cell expansion
after injury, and during adult life.
In contrast, endogenous islet regeneration has been shown to occur through the activation
of ductal-resident progenitor cells that may contribute to new islet formation. Inada et al.122
used a lineage tracing approach to determine if ductal progenitors gives rise to β cells after
ductal ligation in the adult pancreas. These researchers used the reporter gene βgalactosidase (β-gal) to trace carbonic anhydrase II+ ductal cells. After ductal ligation, the
number of β-gal+ β cells increased, which suggests that islet regeneration occurs through
the differentiation of ductal cells, into insulin expressing β cells. Furthermore, Xu et al.123
used pancreatic ligation as an injury model, and a neurogenin 3 (Ngn3) reporter to trace
Ngn3+ endocrine precursor present in the ducts. Upon injury, these cells were activated in
the ducts and could give rise to all endocrine cell types in situ, and in embryonic explant
cultures. These studies suggests that the islet neogenic program may also be activated after
pancreas injury.
In addition, Rovira et al.124 showed that adult mouse ALDH+ centroacinar and terminal
duct (CA/TD) cells highly express progenitor cell markers Sca1, Sdf1, c-Met, Nestin, and
SOX9. Notably, these ALDH+ CA/TD cells were able to form pancreatosphere colonies
in vitro, that demonstrated spontaneous endocrine and exocrine differentiation, as well as
glucose responsive insulin secretion. When ALDH+ CA/TD cells were injected into mouse
embryonic dorsal pancreatic buds these cells also differentiated into both endocrine and
exocrine lineages. Finally, ALDH+ CA/TD cells in the pancreas expanded in the setting of
chronic epithelial cell injury. In addition, Li et al.125 showed that ALDH+ human fetal
pancreas cells highly express progenitor cell markers. High ALDH expression was
observed in newly differentiated insulin+ cells, and overall ALDH-expression was
decreased as development progressed. Interestingly, pharmacological inhibition of ALDH
activity resulted in reduced endocrine cell differentiation, which was reversed by with cotreatement of an RAR/RXR agonist. Collectively, these studies suggest that ALDH+ cells
represent a pool of progenitors that may contribute to the maintenance of pancreatic tissue
homeostasis in the adult mouse and human fetal pancreas.
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Figure 1.4 Mechanisms of endogenous islet regeneration in the post-natal pancreas.
Schematic representation of the proposed mechanisms of endogenous islet regeneration
(adapted from Bonner-Weir et al.36). The proliferation of pre-existing β cells and the
differentiation of intra-islet pancreas-derived multipotent progenitor (PMP) cells has been
shown to give rise to new β cells. Alternatively, islet neogenesis, via the differentiation of
Ins+, Ngn3+, and CAII+ ductal progenitor cells and ALDH+ centroacinar and terminal
ductal (CA/TD) progenitor cells has also been implicated in restoring β cells.
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Although, research is required to delineate the mechanism of endogenous islet
regeneration, finding a therapeutic strategy that “tips the balance” in favour of islet
regeneration versus destruction will be beneficial therapeutic strategy to treat diabetic
patients.

1.8.2.3 Blood Progenitors Stimulate Endogenous Islet Proliferation
and Revascularization
Bell et al.’s126,127 studies provide insight into the potential mechanisms by which BM and
UCB derived human progenitor cells stimulate endogenous islet regeneration (Figure 1.5).
Bell and colleagues found that, i.v. transplantation of BM derived ALDHhi progenitor cells,
and not ALDHlo BM cells improved systemic hyperglycemia and augmented insulin
production in STZ-NOD/SCID diabetic mice.126 In addition, only certain Multipotent
Stromal (MSC) samples derived from BM improved the islet function of STZ-NOD/SCID
diabetic mice. Interestingly, the islet regenerative program activated depends on the
lineage-restriction of the progenitor cell administered. ALDHhi progenitor cells derived
from BM engrafted around the damaged islets, and secreted paracrine factors to stimulate
islet specific-vascularization and islet-associated cell proliferation. This resulted in an
increase islet size (islet circumference), and β cell mass. In contrast, i.v. transplanted MSC
did not engraft in the pancreas or stimulate islet proliferative or pro-angiogenic programs.
Instead, MSC improved systemic hyperglycemia by stimulating the formation of β cell
clusters associated with cytokeratin (CK19) + ductal epithelium, which resulted in an
increase in islet number, suggestive putative neogenic mechanism, whereby MSC stimulate
CK19+ cells to differentiate into insulin+ β cells.
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Figure 1.5 Endogenous islet regeneration after the transplantation of human
BM/UCB-derived ALDHhi progenitor cells or BM-derived MSC. Schematic
representation of mechanisms involved in islet regeneration after the transplantation of
progenitor cells (adapted from Bell et al.128). Transplantation of ALDHhi cells augmented
islet size and vascularization, by stimulating β cell and endothelial cell proliferation, but
did not increase islet number. Transplantation of MSC induced an increase in β cell clusters
associated with CK19+ ducts, which also resulted in an increased β cell mass. Thus, the
islet regenerative program activated depends on the lineage restriction of the progenitor
cell administered.
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In addition, ALDHhi progenitor cells isolated from UCB stimulated endogenous islet
regeneration. Intravenously injected ALDHhi UCB progenitor cells demonstrated lowpancreas engraftment, and only transiently improved islet function.127 Whereas, intrapancreatic (iPan) transplantation ALDHhi UCB progenitor cells, and not ALDHlo UCB
cells improved systemic hyperglycemia, augmented insulin production, and improved
glucose tolerance in STZ-NOD/SCID diabetic mice. Similar to ALDHhi progenitor cells
isolated from the BM, iPan transplanted ALDHhi UCB cells surrounded the damaged
pancreas, and stimulated the islet associated-cell proliferation and islet angiogenesis.126,127
To identify paracrine effectors secreted by ALDHhi UCB that stimulated islet regeneration,
the mRNA transcripts of islet regenerative ALDHhi UCB cohort was compared to the nonregenerative ALDHlo UCB cohort.128 ALDHhi UCB highly expressed the ligands of the
epidermal growth factor receptor (EFGR) superfamily amphiregulin (AREG), epiregulin
(EREG). The EGFR superfamily has been implicated in the regulation of pancreatic β cell
mass. Also, EGFR signaling was essential for the β cell mass expansion in response to a
high fat diet or pregnancy. Furthermore, ALDHhi UCB highly expressed pro-angiogenic
cytokines such as angiopoietin 1 (ANGPT1) and vascular endothelial growth factor A
(VEGF A). In contrast, islet regenerative MSC highly expressed the transcripts of fibrillin
2 (FBN2)-a modulator of transforming growth factor β (TGFβ) bioavailability-WISP1
(WNT1 inducible signaling pathway protein 1) and SFRP1 (Secreted frizzled-related
protein 1)-matrix modifiers downstream of WNT-signaling. Both the TGFβ signaling, and
WNT-signaling are required for pancreatic lineage development. This study suggests that,
AREG, EREG, VEGF and ANGPT1 are involved in supporting β cell proliferation, and
islet angiogenesis. Whereas, WSP1 and FBN2 are involved in supporting islet neogenesis.
However, further research is required to elucidate the progenitor cells and paracrine factors
that formulates the islet regenerative niche, to maximize the endogenous regenerative
potential of the endocrine pancreas.
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1.8.2.4 Clinical Trials Using Blood Progenitor Cells to Treat Diabetic
Patients
In 2005 an Argentine team infused mononucleated cells derived from the human BM
directly into the pancreas through the splenic artery to stimulate endogenous islet
regeneration in type 2 diabetic patients.129 Eighty-four percent of the patients that received
this transplant were weaned off hypoglycemic pharmacological agents. In another study,
25 type 2 diabetic patients received a combination therapy of autologous stem cell infusion
and peri-infusion of hyperbaric oxygen treatment. Compared to baseline before treatment
metabolic variables such as: fasting glucose, HbA1c, fasting c-peptide, and the insulin
requirement improved in these patients 12 months after treatment.130 Although these
preliminary results are exciting, our studies show that it is only blood-derived progenitor
cells that stimulate robust endogenous islet regeneration. Whereas, blood-derived
mononuclear cells do not have this effect.126–128 UCB is a readily available source of bloodderived progenitor cells, however there is not enough of these progenitor cells in UCB to
treat a human diabetic patient. Thus, in order for stem cell infusion to be used as a curative
and sustainable therapy for diabetic patients, progenitor cells must be expanded, and the
mechanism by which these cells stimulate endogenous islet regeneration must be
understood.
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1.9 Hypothesis and Objectives
The overall objective of my project was to characterize UCB-derived, ALDHhi HPC
expanded in clinically applicable serum-free culture conditions. In addition, we aimed to
determine whether these expanded HPC subsets, selected for low versus high ALDH
activity after culture, stimulate endogenous islet regeneration after transplantation in vivo.
We hypothesize that HPC retaining high ALDH activity during ex vivo expansion, will
possess islet regenerative capacity, and will lead to the recovery of hyperglycemia after
transplantation into diabetic mice. We further hypothesize that ALDHhi HPC will secrete
developmental cytokines that stimulate β cell proliferation and islet revascularization.
My first objective was to characterize the cell surface phenotype and hematopoietic colony
formation of human UCB ALDHhi cells after ex vivo expansion over a 9 day time course.
My second objective was to investigate the mechanisms by which culture-expanded
ALDHhi HPC could stimulate islet regeneration and recovery from hyperglycemia after
transplantation into STZ-NOD/SCID mice.
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2.1 Introduction
With approximately one trillion (1012) cells arising daily in the adult human BM, blood is
one of the most highly regenerative tissues in the body. Therefore, it is a rich source of
adult progenitor cells that can be utilized for novel cell therapies.1 Besides hematopoietic
repopulating capacity progenitor cells derived from BM demonstrate tissue regenerative2–
5

, immunomodulatory6, and angiogenic properties.7,8 Furthermore, in a seminal publication

investigating the effect of BM cells on islet regeneration, Hess et al.,9 showed that the
transplantation of murine BM progenitor cells reduced hyperglycemia in STZ treated
diabetic mice by stimulating β cell proliferation and enhancing insulin production in
recipient derived islets in situ via undetermined paracrine mechanisms. This concept
termed “progenitor cell-stimulated islet regeneration” has become a central process for
pancreas repair as evidence now suggest multiple progenitor subtypes induce islet
regeneration either by stimulating β cell expansion, or neoislet formation.10–13
Curative therapies that re-establish functional β cell mass in patients with diabetes has been
an area of intense pre-clinical studies over the past 10 years. There are two distinct types
of diabetes; type 1 diabetes is associated with the autoimmune destruction of insulin
secreting β cells, while type 2 diabetes is linked to a combination of insulin resistance, β
cell dysfunction, and ultimately β cell failure.14,15 Currently, the symptoms associated with
the β cell dysfunction in both type 1 and type 2 diabetic patients are treated using exogenous
insulin. Furthermore, oral hypoglycemic agents like metformin are currently used to treat
the peripheral insulin resistance observed in type 2 diabetic patients. Since, these
treatments do not provide the same “on-demand” glycemic control, diabetic patients have
more extreme peaks and troughs in blood glucose levels.16 As a result, more than 90% of
diabetic patients develop severe vascular complications, including peripheral limb
ischemia, heart attack, and stroke.17 In patients with severe diabetes, the success of whole
pancreas or isolated islet transplantation via the Edmonton protocol suggests that
hyperglycemia can be controlled by the replacement of viable β cells.18 However,
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prevented the widespread use of these procedures.19,20 Interestingly, the medalist study has
shown that, type 1 diabetic patients with disease duration >50 years have sustained resting
c-peptide levels, suggesting residual β cell function.17 Also, immunohistochemical analysis
of 9 patients that died during the study revealed the presence of proliferating insulin+ cells
in the pancreas.17 Thus, stimulating the regeneration of endogenous β cells in situ, may
represent a feasible approach to improve endogenous insulin production in diabetic
patients.
In addition to BM, UCB represents a readily available source of progenitor cells. The
widespread initiatives to HLA-phenotype and cryopreserve human UCB in North America
and Europe, has ensured that UCB represents a sustainable source of post-natal progenitor
cells, for cell therapy applications. In our most recent studies, we used human UCB cells
with high aldehyde dehydrogenase activity (ALDHhi), a conserved progenitor cell function,
to establish that ALDHhi cells stimulate endogenous islet proliferation and
revascularization after direct iPan ransplantation into STZ-NOD/SCID mice.11 However,
the low number of ALDHhi cells found in UCB limits the widespread application of
transplanted UCB-derived progenitor cells to stimulate islet regeneration in human diabetic
patients.
To increase the number of progenitor cells available for clinical application, we expanded
the HPC lineage of ALDHhi UCB cells under clinically applicable, serum-free conditions.
These conditions resulted in a 15-fold increase in total cell number, and a 3-fold increase
in the number of HPC retaining high ALDH activity. HPC that retained high ALDH
activity (ALDHhi HPC) highly expressed primitive hematopoietic cell surface markers
(CD34, CD133), and demonstrated hematopoietic colony forming capacity in vitro.
Culture-expanded ALDHhi HPC transplanted STZ-NOD/SCID mice demonstrated
improved hyperglycemia, and glucose tolerance, increased islet size, and vascularization.
These data identify culture-expanded ALDHhi HPC as a novel cell population for clinical
applications, and provide strong justification for the further enhancement of expansion, reselection, and transplantation strategies using UCB-derived HPC to tip the balance in
favour of islet regeneration versus destruction in patients with diabetes.
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2.2 Methods
2.2.1 ALDHhi Progenitor Cell Isolation from Human Umbilical Cord
Blood
Human UCB (N=10) was obtained with informed consent following cesarian section, by
phlebotomy of the umbilical vein, at the Victoria Hospital Birthing Centre in London.
Within 24 hours, UCB samples were lineage depleted (Lin-, RosetteSep™ Human Cord
Blood Progenitor Cell Enrichment Cocktail, StemCell Technologies, Vancouver, Canada)
and the mononuclear cells (MNC) were isolated by Hypaque Ficoll centrifugation. Lindepleted MNC were incubated with the AldeflourTM reagent (StemCell Technologies), and
fluorescence activated cell sorting (FACSAria, BD Biosciences, Mississauga, ON) was
used to isolate cells with low side scatter and high ALDH-activity.

2.2.2 Ex vivo Expansion of UCB ALDHhi Cells
For ex vivo HPC expansion, freshly isolated ALDHhi UCB cells were plated into
fibronectin coated plates in X-vivo 15 media (Lonza, Basel, Switzerland) supplemented
with-SCF, FLT-3L, and TPO-at a concentration of 10ng/mL (Invitrogen, Burlington, ON).
UCB ALDHhi cells were cultured for 3, 6, or 9 days, with a media change every 3 days.

2.2.3 Characterization of Cell Surface Marker Expression on CultureExpanded HPC
Day 0 fresh ALDHhi UCB or day 3, 6, or 9 culture-expanded HPC were collected and
stained with anti-human antibodies for CD3 (T cells), CD14 (monocytes), CD19 (B cells)
(all BD Biosciences), and HPC markers CD34 (Biolegend, San Diego, CA), CD133
(Miltenyi Biotec, Auburn, CA). Cells were co-stained with Aldeflour™ to determine
ALDH activity, and cell viability was assessed by trypan blue viability counts and costaining with 7-amino-actinomycin D (BD Biosciences). Cell surface marker expression
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was acquired using a LSRII flow cytometer at the London Regional Flow Cytometry
Facility, and analyzed using FlowJo software.

2.2.4 Methylcellulose Assay
Six day culture-expanded unsorted (Bulk) HPC, ALDHhi HPC or ALDHlo HPC
subpopulations were seeded in methylcellulose media (H4434, Stem Cell technologies) at
cell density of 1000 in duplicate or triplicate, and the hematopoietic colonies formed were
phenotyped by light microscopy, and enumerated after 14 days.

2.2.5 Transplantation of Culture-Expanded HPC Subsets into STZNOD/SCID Mice
Adult (7-12 week) NOD/SCID mice (Jackson Laboratories, Bar Harbor ME) were injected
with STZ (35mg/kg/day) for 5 days. On day 10 these mice were sub-lethally irradiated
(300cGy) and transplanted by i.v. injection with PBS or with 5×105 Bulk HPC, 2×105
ALDHlo HPC, or 2×105 ALDHhi HPC. Systemic blood glucose concentrations were
monitored weekly for 42 days. Twenty-four hours prior to sacrifice, mice were injected
with 5-ethynyl-2’-deoxyuridine (EdU, Invitrogen) to mark proliferating cells, and glucose
tolerance tests (2 hour duration) were performed after intraperitoneal injection of 2mg/kg
glucose. The BM, and the duodenal (pancreas head) portion of the pancreas were collected
and analyzed for engraftment of human cells expressing human pan-leukocyte specific
marker CD45, and human nucleated cell marker HLA-A,B,C by flow cytometry.
Previously, it has been shown that islet neogenesis occurs in the splenic (pancreas tail)
portion of the pancreas.21 Therefore, to characterize the islet regenerative program
stimulated by transplanted progenitor cells, the tail of the pancreas was harvested frozen
and sectioned at 10 µm for immunohistochemical analysis, using a cryostat such that each
slide contained 3 sections that were 150 µM apart, belonging to one mouse, to ensure that
the same islet was not counted twice. For all subsequent immunohistochemical staining
procedures the appropriate controls-primary antibody only, secondary antibody only-were
performed to control for background staining.
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2.2.6 Islet Size, Number, and β Cell Mass Quantification
For islet analysis each section was fixed with 10% buffered formalin for 15 minutes
(Sigma, St. Louis, MO), washed with PBS, and blocked with peroxidase block for 5
minutes and mouse-on-mouse reagent for an hour (Vector, Burlington, ON). Afterwards,
sections were incubated for 5 minutes with mouse-on-mouse protein diluents (Vector).
Sections were then incubated with mouse insulin antibody (diluted 1/1000, Sigma) for an
hour, which was detected with a secondary peroxidase labeled rabbit anti-mouse IgG
antibody (1 hour incubation, diluted 1/200, Vector) and ImmPACT™ DAB (Vector), then
counterstained with hematoxylin and mounted in vectamount (Vector). Islets were detected
using a light microscope (BX50, Olympus, Richmond Hill, ON). In each section islets with
a circumference above 150µm in 4 randomly selected areas (1mm2) were counted, and
analyzed using the Northern Eclipse Software. β cell mass was calculated using the
formula: (βcell area)/(total area – β cell area) × pancreas weight.

2.2.7 Islet Blood Vessel Density Quantification
In order to quantify blood vessels, each of the sections were first fixed with 10% buffered
formalin for 15 minutes (Sigma), washed with PBS, permeabilized with 1 % Trition X-100
(Sigma) for 20 minutes, and blocked with mouse-on-mouse reagent (vector) for an hour,
and incubated for 5 minutes with mouse-on-mouse protein diluents (Vector). Afterwards,
sections were incubated with mouse anti-mouse insulin primary antibody (1 hour
incubation time, diluted 1/100, Sigma), which was detected using the Texas Red-labeled
horse anti-mouse secondary antibody (1/200, Vector). Each section was first blocked with
rabbit blocking buffer for an hour, then co-stained with rat anti-mouse CD31 antibody (1
hour incubation, diluted 1/200, Chemicon, Temecula, CA), which was detected using
Fluorescein-labeled rabbit anti-rat IgG secondary antibody (30 minute incubation, diluted
1/200, Vector).The slides were then mounted in VectaShield with DAPI (Vector). The
fluorescence microscope (Axio Scope Z2) and the AxioVision software were used to detect
CD31+ vessels within islets, and in extra-islet regions. In each section intra-islets blood
vessels, extra-islet blood vessels, and DAPI stained nuclei within the islet were quantified.
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CD31 vessels/islet cell was calculated using the formula: intra-islet CD31+ vessels/intraislet DAPI stained nuclei.

2.2.8 Quantification of Proliferating Cells
Each section was fixed with 10% buffered formalin (Sigma) for 15 minutes, washed with
PBS for 20 minutes, permeabilized with 1 % Trition X-100 (Sigma) for 20 minutes. EdU+
cells were detected using the Click-iT™ EdU imaging kit (Invitrogen) as per
manufacturer’s protocol, and co-stained for insulin as described in the islet blood density
protocol above. The fluorescence microscope (Axio scope Z2, Germany) and the
AxioVision software were used to detect proliferating islet cells. EdU+ cells in each islet,
the number of islets with at least one EdU+ cell, and DAPI nuclei were then quantified.
Percentage of EdU+ islet cells was calculated using the following formula: (EdU+ islet
cells/intra-islet DAPI stained nuclei) × 100. Percentage of islets with at least one EdU+ cell
was calculated using the following formula: (islets with at least 1 EdU+ islet cell/the total
number of islets) × 100.

2.2.9 RNA Isolation and Microarray Analyses
mRNA was isolated from 6 day culture-expanded ALDHhi and ALDHlo HPC in triplicate
using the mRNeasy Mini kits (Qiagen, Dusseldorf, Germany). Microarray was performed
using human array chips (Affymetrix, Santa Carla, CA) at the London Regional Genomic
Center. mRNA transcripts that were significantly (p<0.05) increased by 1.5-fold in
ALDHhi HPC vs. ALDHlo HPC (p<0.05) were identified, and then filtered for documented
angiogenic function using the Partek Genomic Suite (Partek, Inc., St. Louis, MO).

2.2.10 Statistical Analysis
All data was expressed as mean ± standard error of the mean (SEM). Analysis of
significance was performed by a two-way analysis of variance (ANOVA) for the blood
glucose curve, and by one way ANOVA, followed by Tukey’s test for all other analyses
unless otherwise stated.
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2.3 Results
2.3.1 Cells Retaining High ALDH-activity and Primitive Progenitor
Phenotype was maximized after 6 Days of Culture
Hematopoietic progenitor enriched human UCB Lin- cells were FACS purified based on
low side scatter and high ALDH activity (Figure 2.1A-C), 1.7 ± 0.3% of UCB Lin- cells
demonstrated high ALDH activity (N=10). We have previously shown purified ALDHhi
cells represent a heterogeneous progenitor cell population, primarily composed of
primitive hematopoietic and early myeloid progenitor cells, with murine islet regenerative
and proangiogenic potential.7,11 Specifically, ALDHhi UCB highly co-expressed the
hematopoietic progenitor cell markers CD34 (91.6±1.8%), and CD133 (62.2±5.7%, Figure
2.2). We typically accrue a total of 2-4×105 from a UCB sample, and the low number of
ALDHhi cells found in UCB limits the widespread application of transplanted UCB-derived
progenitor cells available for regenerative therapies. Therefore, we adapted clinically
applicable conditions to expand ALDHhi UCB cells in serum free media using the
hematopoietic growth factors: SCF, FLT-3L, TPO.22–26 Under these hematopoietic cell
expansion conditions fresh UCB ALDHhi cells expanded by 2.3 ± 0.4-fold at day 3, 20.7±
2.0-fold at day 6, and 53.5 ± 9.0-fold at day 9 of culture (Table 2.1, N=5-7). Furthermore,
the frequency of HPC retaining high ALDH-activity diminished as culture time progressed
from 28.7 ± 2.0% at day 3, versus. 14.9 ± 3.9 % day at 6, versus. 2.2 ± 0.3% at day 9,
(Figure 2.1D-F). Interestingly, at day 6 the culture expanded HPC population demonstrated
the highest number of total ALDHhi (3.09 ± 1.1 fold, Figure 2.1G), ALHDhi/CD34+ (2.24
± 0.31 fold, Figure 2.1H), and ALDHhi/CD133+ (1.84 ± 0.37 fold, Figure 2.1I) primitive
progenitor cells. Therefore, we selected 6 day culture-expanded HPC for all further
analyses.
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Figure 2.1 Isolation and expansion kinetics of human UCB ALDHhi cells.
Representative flow cytometry plots showing the initial purification of human UCB
ALDHhi cells. Lineage depleted UCB cells were first gated using (A) forward and side
scatter properties. (B) DEAB-treated controls were used to establish gates for the selection
of (C) ALDHhi cells using the AldefluorTM assay. Purified UCB ALDHhi cells represented
1.7±0.3% of the total Lin- cell population. (D-F) Representative FACS analysis showing
the frequency of culture-expanded HPC that retained high ALDH-activity after culture for
3, 6, or 9. The frequency of HPC retaining high ALDH-activity was diminished as culture
time progressed. (G-I) Total cell expansion at days 3, 6, or 9 for ALDHhi cells,
ALDHhi/CD34+ cells, and ALDHhi/CD133+ cells compared to the number of cells of each
subset seeded at day 0. At day 6 cultured HPC demonstrated highest expansion of ALDHhi
cells, ALDHhi/CD34+ cells, and ALDHhi/CD133+ cells compared to 3 day or 9 day cultured
HPC. Data represent mean ± SEM from 5-7 UCB samples (a<b, p<0.05).
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Figure 2.2 . Fresh UCB cells with high ALDH-activity (ALDHhi UCB) co-expressed
hematopoetic progenitor cell surface markers. Representative flow cytometry plots
showing the analysis of fresh ALDHhi progenitor cells isolated from Lin- UCB.
Specifically, flow cytometry plots of (A) Isotype control (B) of primitive cell surface
markers expressed on fresh ALDHhi UCB cells. Data represent mean ± SEM from 3 UCB
samples.

51

Table 2.1 Total cell expansion of ALDHhi UCB cells after 3, 6, or 9 days of culture.

Human ALDHhi UCB cells were cultured for 3, 6, or 9 days, and total cell number and total
cell fold expansion was quantified at each time point, by comparing the number cells at
each day to the number of ALDHhi cells seeded at day 0. Data represent mean ± SEM from
5-7 UCB samples.
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2.3.2 The Culture-Expanded ALDHhi HPC Subset Co-Expressed
Primitive Hematopoietic Progenitor Cell Surface Markers
After 6 days of expansion 14.9±3.9% of cells retained high ALDH activity (Figure 2.1E).
Therefore, the 6 day culture-expanded HPC population was categorized as Bulk HPC,
ALDHlo HPC, and ALDHhi HPC subsets based on DEAB controls (Figure 2.3A-C), and
each population was subsequently analyzed for primitive hematopoietic cell surface
markers. Cell surface molecules such as CD34, and CD133 are commonly used to isolate
primitive hematopoietic cells with in vitro and in vivo repopulating function. The
expression of these molecules diminish with maturation and differentiation.1,27,28 These cell
surface molecules were highly expressed on freshly isolated BM, and UCB ALDHhi
progenitor cells with islet regenerative functions (Figure 2.2).8,11,12 Compared to the Bulk
HPC, and ALDHlo HPC, the ALDHhi HPC subset was highly enriched for primitive
hematopoietic cell surface markers (69.3 ± 6.4% CD34+, 40.3 ± 8.1% CD133+, Table 2.2).
In addition, the islet regenerative BM and UCB derived ALDHhi progenitor cells are
enriched for CD34+/CD38- and CD34+/CD133+ primitive progenitor populations (Figure
2.2).8,27 ALDHhi HPC showed a significantly higher frequency of cells expressing this
primitive hematopoietic progenitor cell phenotype (34.8 ± 6.6% CD34+/CD38-, 41.6 ±
7.4% CD34+/CD133+, Figure 2.2D-J) compared to Bulk HPC and ALDHlo HPC subsets.
Notably, ALDHhi HPC did not acquire mature monocyte (0.4±0.1% CD14+, Table 2.2) or
macrophage markers (0.8 ±0.2% CD11b+,Table 2.2). These data suggests that the 6 day
culture-expanded ALDHhi HPC sub-population retains a primitive hematopoietic
progenitor phenotype, without full differentiation to the monocyte or macrophage lineage.
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Figure 2.3 Culture-expanded cells retaining high ALDH-activity (ALDHhi HPC) coexpressed progenitor cell surface markers and demonstrated hematopoietic colony
forming function in vitro. Representative flow cytometry plots showing the analysis of
expanded HPC subsets after 6 days culture. (A) DEAB controls were used to establish gates
for (B) Bulk HPC and (C) ALDHlo versus ALDHhi HPC subsets. (D-I) Representative flow
cytometry plots of primitive cell surface markers expressed on expanded HPC subsets. (J)
ALDHhi HPC showed significantly higher frequency of cells expressing a primitive HPC
phenotype (CD34+/CD38-, CD34+/CD133+). (K-L) Bulk HPC, ALDHlo HPC, or ALDHhi
HPC were cultured in MethylcelluloseTM media and colonies of erythrocyte, granulocyte,
and macrophage lineages were enumerated after 14 days. ALDHhi HPC were enriched for
total hematopoietic colony forming cells, and ALDHhi HPC formed significantly more
erythroblast, and granulocyte colonies compared to ALDHlo HPC. Data represent mean ±
SEM from 5-6 UCB samples (a<b<c, p<0.05).
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Table 2.2 Analyses of Bulk HPC, ALDHlo HPC, and ALDHhi HPC for expression of
hematopoietic cell surface markers.

ALDHhi HPC demonstrated increased levels of primitive cell surface markers (CD34 and
CD133) compared to Bulk HPC and ALDHlo HPC. Data represent mean ± SEM from 4-6
UCB samples (a<b, p<0.05).
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2.3.3 The Culture-Expanded ALDHhi HPC Subset Contained
Multipotent Hematopoietic Colony Forming Cells
In order to determine whether ALDHhi HPC retained hematopoietic colony forming cell
activity after 6 days of expansion, Bulk HPC or ALDHlo HPC or ALDHhi HPC were plated
in methylcellulose media, and the clonogenic hematopoietic colonies formed were
enumerated after 14 days. Compared to ALDHlo HPC, the ALDHhi HPC subset was
enriched for total multipotent hematopoietic colony cells (9.6 ± 0.7% ALDHhi HPC versus.
6.1 ± 1.7 ALDHlo HPC, Figure 2.3K). Particularly, ALDHhi HPC formed significantly
more erythroblast, and granulocyte colonies compared to ALDHlo HPC (Figure 2.3L).
Therefore, the ALDHhi HPC subset retained a greater hematopoietic colony forming
capacity compared to the ALDHlo HPC subset.

2.3.4 Transplantation of Culture-Expanded ALDHhi HPC Improved
Islet function.
Our group has previously found that the transplantation ALDHhi UCB improved the islet
function of STZ-NOD/SCID diabetic mice.11 However, the low number of ALDHhi cells
found in UCB limits the widespread application of transplanted UCB-derived progenitor
cells to treat diabetes. Therefore, our goal was to expand ALDHhi UCB cells, in
hematopoietic culture, while retaining its islet regenerative functions. To investigate the
islet regenerative capacity of fresh ALDHhi UCB-derived, culture-expanded HPC
populations in vivo, STZ-treated NOD/SCID mice were i.v. injected with PBS or 5×105
Bulk HPC on day 10, and blood glucose levels were assessed until day 42 (Figure 2.4A).
Similar to PBS-injected controls, mice i.v. transplanted with Bulk HPC remained severely
hyperglycemic (>25mmol/L,Figure 2.4B), suggesting a loss of islet regenerative function
in the Bulk HPC population, as a result of 6 day ex vivo expansion. Therefore, the Bulk
HPC were re-selected after culture expansion by FACS for the sub-populations with low
(ALDHlo HPC) versus high ALDH (ALDHhi HPC) activity (as seen in figure 2.3C). After
i.v. transplantation of 2×105 cells, mice transplanted with ALDHlo HPC remained severely
hyperglycemic (>25mmol/L,Figure 2.4B). Remarkably, mice transplanted with an equal
dose ALDHhi HPC demonstrated reduced systemic glucose levels from day 17-42
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Figure 2.4 Transplantation of culture-expanded ALDHhi HPC improved
hyperglycemia and glucose tolerance in STZ-NOD/SCID mice. (A) STZ-NOD/SCID
mice (35mg/kg/day, days 1-5) were sublethally irradiated and i.v. injected with PBS (blue,
n=8 mice); 5x105 Bulk HPC (orange, n=9 mice), 2x105 ALDHlo HPC (red, n=9 mice), or
2x105 ALDHhi HPC (green, n=9 mice) on day 10 and blood glucose levels were monitored
for 42 days. (B) Compared to mice transplanted with PBS, Bulk HPC or ALDHlo HPC,
mice transplanted with ALDHhi HPC showed reduced resting blood glucose levels from
days 17-42, and (C) reduced area under the curve. (D) At day 41 a glucose tolerance test
was performed on mice transplanted with PBS (n=3) ALDHlo HPC (n=9) and ALDHhi HPC
(n=9). Compared to PBS-injected or ALDHlo HPC, mice transplanted with ALDHhi HPC
showed improved glucose tolerance, and (E) reduced area under the curve. Data represent
mean ± SEM from 5-7 UCB samples (a<b, p<0.05; *p<0.05).
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compared to mice from all other treatment groups (Figure 2.4B). After performing area
under the curve (AUC) analyses on all i.v.-transplanted mice, ALDHhi HPC transplanted
mice showed significantly reduced hyperglycemia compared to all other treatment groups
(Figure 2.4C). Furthermore, compared to mice transplanted with PBS or ALDHlo HPC,
mice transplanted with the culture-expanded ALDHhi HPC subset showed improved
glucose tolerance (Figure 2.4D-E). This suggests that the i.v. transplantation of ALDHhi
HPC subset improved the glucose response in STZ-NOD/SICD mice.

2.3.5 Culture-Expanded ALDHhi HPC Engrafted in the Murine BM
To correlate the improvement of glycemic control with human cell engraftment the BM
and the head of the pancreas was collected at day 42, and analyzed for the presence of
human CD45+ and HLA-ABC by flow cytometry. Only the culture-expanded ALDHhi
HPC subset consistently engrafted in the murine BM, however human cells were not
detected in the murine pancreas by flow cytometry at day 42 (Figure 2.5A-C). Although,
analysis at earlier time points is required to delineate the recruitment kinetics of ALDHhi
HPC to the injured pancreas of STZ-NOD/SCID mice after i.v. injection, our previous
studies with freshly isolated ALDHhi UCB cells have documented low level pancreas
engraftment at 7 day post-transplantation.12
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Figure 2.5 Engraftment of human UCB-derived ALDHhi progenitor cells in the BM
and pancreas of STZ-NOD/SCID mice. (A) Representative flow cytometry plots of
human cell engraftment at day 42 in the BM and pancreas of recipient mice i.v. transplanted
with Bulk HPC (n=9), ALDHlo HPC (n=9), or ALDHhi HPC (n=9). (B) Transplantation of
ALDHhi cells, but not Bulk HPC or ALDHlo HPC, resulted in consistent human
hematopoietic chimerism in mouse BM. (C) Bulk HPC, ALDHlo HPC or ALDHhi HPC
were not detected in the mouse pancreas at day 42. Data Represents Mean ± SEM from 57 UCB samples.
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2.3.6 Transplantation of Culture-Expanded ALDHhi HPC Increased
Islet Size, and β Cell Mass
To determine the mechanisms by which ALDHhi HPC improved glycemic control,
pancreas sections of transplanted mice were stained for murine insulin (Figure 2.6A-D),
and analyzed for islet size (Figure 2.6E), islet number (Figure 2.6F), and total β cell mass
(Figure 2.6G). Mice transplanted with Bulk HPC, and ALDHlo HPC had a similar islet size,
islet number and β cell mass as PBS injected controls. In contrast, ALDHhi HPC
transplanted mice showed a significant (p<0.05) increase in islet size (circumference), and
β cell mass, but not islet number compared to mice from all other treatment groups. All
islets were derived from murine cells suggesting that transplantation ALDHhi HPC
improves islet function by stimulating an endogenous islet regeneration.

2.3.7 Transplantation of Culture-Expanded ALDHhi HPC Increased
Islet Vascularization
We postulated that improved hyperglycemia (Figure 2.4) and increased islet size (Figure
2.6E) after culture-expanded ALDHhi HPC transplantation may also correlate with
progenitor-stimulated islet vascularization.7,11,12 Thus, mouse pancreas sections were
stained with murine insulin and CD31-a marker of endothelial cells within blood vessels
at day 42 (Figure 2.7 A-F). The intra-islet and extra-islet microvessel densities in mice
transplanted with Bulk HPC and ALDHlo HPC were similar to PBS injected mice (Figure
2.7A-C). Interestingly, mice transplanted with ALDHhi HPC showed augmented islet
vascularization with increased numbers of CD31+ cells (Figure 2.7D, arrowheads).
Furthermore, higher zoom of the representative inset shows CD31 expressing cells in close
association with insulin+ β cells within the regenerating islet (Figure 2.7E), and CD31+
cells

were

distinct

and

formed

continuous

vessels

(Figure

2.7F,

arrows).

Histomorphometric quantification of intra-islet capillary density was significantly
increased (p<0.05) in ALDHhi HPC transplanted mice, compared to all other treatment
groups (Figure 2.7F). Interestingly, similar analyses quantifying extra-islet vascularization
were equivalent (Figure 2.7H), when compared to mice from all other treatment groups.
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Figure 2.6 Transplantation of culture-expanded ALDHhi HPC increased islet size and
β cell mass without increasing total islet number. Representative photomicrographs of
islet structures (brown) at day 42 in STZ-NOD/SCID mice i.v. injected with (A) PBS (n=6),
(B) Bulk HPC (n=9), (C) ALDHlo HPC (n=5), or (D) ALDHhi HPC (n=6). Compared to
PBS controls, or mice transplanted with Bulk HPC or ALDHlo HPC, mice transplanted
with ALDHhi HPC showed (E) significantly increased islet circumference, (F) equivalent
islet number, (G) and increased β cell mass. Data represent mean ± SEM from 3-6 UCB
samples (a<b, p<0.05).
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Figure 2.7 Transplantation of culture-expanded ALDHhi HPC increased islet
vascularization. Representative photomicrographs of CD31+ blood vessels (green)
associated with insulin+ islets (red) at day 42 in STZ-NOD/SCID mice transplanted with
(A) PBS (n=7), (B) Bulk HPC (n=9), (C) ALDHlo HPC (n=5), or (D) ALDHhi HPC
(n=8). Arrowheads mark CD31+ cells within islets. (E) Higher zoom of the inset shown in
(D) clearly shows CD31+ cells in close association with insulin expressing β cells within
regenerating islets. (F) Transplantation of UCB ALDHhi HPC also induced the appearance
of CD31+ vessel structures within and immediately surrounding insulin+ islets. Arrows
mark CD31+ continuous vessels. (G) Compared to mice transplanted with PBS, Bulk HPC,
and ALDHlo HPC, mice transplanted with ALDHhi HPC showed increased vascularization
within islets, but not in (H) extra-islet areas. Data represents mean ± SEM from N=3-6
UCB samples (a<b, p<0.05).
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These data suggest that transplantation of ALDHhi HPC stimulated islet-specific
revascularization.

2.3.8 Mice Transplanted with Culture-Expanded ALDHhi HPC
Demonstrated an Increase in Proliferating Islets
To further investigate an increase in islet size, EdU incorporation into proliferating islets
were analyzed at day 42 (Figure 2.8A-D). According to a student’s t-test, compared to mice
transplanted with PBS, ALDHhi HPC transplanted mice demonstrated a significantly
higher % EdU+ islet cells (Figure 2.8E), and a significant increase (p<0.05) in the % islets
with at least one EdU+ proliferating cell (Figure 2.8F). Our previous studies with freshly
isolated ALDHhi cells have documented augmented islet proliferation at 7 day posttransplantation.12

Although analyses of islet proliferation at earlier time points were not

performed, these data suggest that transplantation of culture-expanded ALDHhi HPC
stimulated islet proliferation.

2.3.9 Culture-Expanded ALDHhi HPC Demonstrated a Pro-angiogenic
Transcription Profile
Affymetrix microarray analyses were performed on three ALDHhi HPC samples compared
to sample matched ALDHlo HPC, and 406 transcripts with significantly (p<0.05) increased
expression were identified. These samples were filtered for documented angiogenic
biological function. As an internal control for the selection of HPC with high ALDH
activity, ALDHA1 mRNA expression was higher by 3.7-fold in ALDHhi HPC versus
ALDHlo HPC (Table 2.2). Furthermore significantly higher CD34, PROM1 (Table 2.3)
mRNA expression in ALDHhi HPC correlated with increased CD34, and CD133 cellsurface protein expression, previously observed by flow cytometry (Table 2.2).
Interestingly, transcripts associated with vascular cell signaling, and angiogenic cytokines
were increased in ALDHhi HPC, compared to the ALDHlo HPC subset (Table 2.4).
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Figure 2.8 Transplantation of culture-expanded ALDHhi HPC increased proliferating
Islets. Representative photomicrographs of EdU+ proliferating cells (green) within insulin+
islets (red) at day 42. STZ-NOD/SCID mice transplanted with (A) PBS (n=4), (B) Bulk
HPC (n=7), (C) ALDHlo HPC (n=4), or (D) ALDHhi HPC (n=7). Arrowheads mark
EdU+ proliferating cells within islets. (E) Compared to mice transplanted with PBS mice
transplanted with ALDHhi HPC showed an increase in percentage of EdU+ cells within
islets and, (F) an increase in the percentage of islets with at least one EdU+ proliferating
cell. Data represent mean ± SEM from 3-5 UCB samples (*p<0.05).
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Table 2.3 . Progenitor cell-associated transcripts encoding progenitor cell markers,
with increased expression in ALDHhi HPC versus ALDHlo HPC

FC Fold change MAPK mitogen-activated protein kinase CD cluster of differentiation.
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Table 2.4 Angiogenesis-associated transcripts encoding secreted proteins, and cell
surface proteins with increased expression in ALDHhi HPC versus ALDHlo HPC

FC Fold change EGF epidermal growth factor TIMP tissue inhibitors of
metalloaproteinases ETS E26 transformation-specific
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2.4 Discussion
These studies demonstrated that the HPC lineage of fresh ALDHhi UCB cells expands
efficiently in culture, and that only the HPC sub-population that retains high ALDH activity
stimulates islet regeneration when i.v.-transplanted into STZ-NOD/SCID mice. UCB
ALDHhi cells expanded in serum-free media supplemented with hematopoietic cytokines
SCF, TPO, and FLT-3L. Although, the highest number of total HPC was observed after 9
days of ex vivo expansion, the highest number of ALDHhi HPC was observed after 6 days
of ex vivo expansion. Interestingly, the culture-expanded ALDHhi HPC subset
demonstrated primitive hematopoietic progenitor cell phenotype, and multipotent colony
formation. In addition, the ALDHhi HPC subset highly expressed pro-angiogenic
transcripts. Transplantation of 6 day culture-expanded ALDHhi HPC also improved islet
function, increased β cell mass, and augmented islet vascularization in STZ-NOD/SCID
mice. Collectively, these data suggest that culture-expanded ALDHhi HPC from human
UCB represent a readily available, and novel population for the development of cellular
therapies to promote endogenous islet regeneration.
UCB ALDHhi progenitor cells were highly proliferative in culture. We achieved a total cell
expansion of 2.3-fold, 20.7-fold, and 53.5-fold after 3, 6, and 9 days of culture,
respectively. Studies have shown that culturing UCB-derived progenitor cells with
hematopoietic cytokines results in a significant expansion of committed progenitor cells,
with only a minimal expansion of primitive progenitor cells.25 We used relative ALDH
activity after culture to distinguish primitive hematopoietic progenitor cells (ALDHhi
HPC), from culture differentiated, more committed progenitor cells (ALDHlo HPC).
Compared to ALDHlo HPC, ALDHhi HPC demonstrated increased expression of primitive
cell surface markers, and were enriched for multipotent colony forming cells in vitro.
Similar to previous studies25,26,29,30, we found that the frequency of primitive progenitor
cells (ALDHhi HPC) declined as culture progressed. Furthermore, committed progenitor
cells in culture have been shown to secrete factors such as TGFβ that limit the proliferation
of primitive progenitor cells.31–36 Due to the accumulation of inhibitory soluble factors in
primary HPC cultures, we wanted to determine the time point that yielded the highest
number of primitive ALDHhi HPC. These analyses revealed that 6 days of ex vivo
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expansion, yielded the highest number of ALDHhi, ALDHhi/CD34+ HPC, and
ALDHhi/CD133+ HPC, with a drastic decrease in HPC with these primitive phenotypes at
day 9. Thus, we characterized the islet regenerative properties using day 6 cultureexpanded HPC subpopulations purified using low versus high ALDH activity.
The endocrine pancreas is a highly vascularized tissue, it has 5-7 times more capillaries
than the surrounding exocrine pancreas tissue.37 A dense capillary network is required for
β cell to optimally sense blood glucose levels, and the fenestrations in the islet capillary
endothelium is the most efficient way for insulin to be secreted by β cells into the systemic
circulation.38 Thus, the islet capillary network is essential for optimal islet function.
Furthermore, hepatocyte growth factor (HFG) secreted by endothelial cells, and laminin
which is presented on the basement membrane of the islet capillary network have been
shown to stimulate β cell proliferation.39,40 Collectively, these studies suggest that
endothelial-endocrine axis plays an important role in supporting β cell function, and β cell
turnover. Previously, we have shown that freshly isolated ALDHhi UCB cells contains proangiogenic progenitor cells that improve perfusion after transplantation into mice with
hind-limb ischemia.7 Here we show that culture-expanded ALDHhi HPC, derived from
freshly isolated UCB cells with high ALDH activity, enhanced islet-specific
vascularization in the STZ-NOD/SICD mouse pancreas. Increased vascularization was
specific to the islets, rather than extra-islet pancreatic tissue, suggesting that cultureexpanded ALDHhi HPC stimulates an islet specific vascularization program after
transplantation into STZ-NOD/SCID mice. Interestingly, an increased vascularization was
associated with an increased islet size, β cell mass, and an improved islet function.
Collectively, our data suggest that ALDHhi HPC improves islet function in STZNOD/SCID mice, by re-establishing the endothelial-endocrine axis.
This study also begins to address the transcriptional, and secretory activities of 6 day
culture-expanded ALDHhi HPC. The transcripts of the secreted proteins Semaphorin 4A
(SEMA4A), Angiopoietin 2 (ANGPT2), and Milk Fat Globule-EGF factor 8 (MFG-E8)
were higher in culture-expanded ALDHhi HPC compared to ALDHlo HPC. The proteins
encoded by these transcripts are all involved in supporting vascular endothelial growth
factor-A (VEGFA) mediated angiogenesis. MFG-E8 also known as lactadherin has been
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shown to interact with αvβ3 integrins on endothelial cells, and has been shown to be critical
in VEGFA induced angiogenesis.41 In the hind-limb ischemic model, injection of antiMFG-E8 blocked VEGFA induced angiogenesis.41 The transcript of ANGPT2 was also
higher in culture-expanded ALDHhi HPC. Studies have shown that, ANGPT2 is a complex
regulator of vascular remodelling that plays a role in both vessel sprouting, and vessel
regression. Studies have suggested that ANGPT2 in the presence of VEGF stimulates
vessel sprouting.42–47 Pancreatic β cells express high levels of VEGF.38,48,49 It is plausible
that MFG-E8, and ANGPT2 secreted by ALDHhi HPC stimulate islet vascularization, by
supporting a VEGF dependent angiogenic program.
Finally, the transcript of SEMA4A was higher in culture-expanded ALDHhi HPC.
SEMA4A has been shown to act on PlexinD1 receptors on macrophages, to stimulate the
release of VEGFA from macrophages.50 The VEGFA subsequently secreted from
macrophages, after SEM4A stimulation exerted a pro-angiogenic effect on endothelial
cells in vitro, and in vivo. Mouse macrophages are recruited to pancreas during injury.51
SEM4A produced by ALDHhi cells may act on the PlexinD1 receptors on these mouse
macrophages to stimulate VEGFA release, which subsequently supports angiogenesis in
the pancreas of STZ-diabetic mice. Collectively, these data suggest that a pro-angiogenic
microenvironment may be established in the pancreas of STZ-NOD/SCID diabetic mice,
after the transplantation of ALDHhi HPC.
Intra-pancreatic transplantation of freshly isolated UCB cells with high ALDH activity
stimulated islet revascularization, and β cell proliferation in STZ-NOD/SCID diabetic
mice, despite the low level of engraftment of UCB ALDHhi cells in the pancreas (0.09 ±
0.03%, n=6 mice), at day 42.11 The freshly isolated ALDHhi UCB cells created a
regenerative niche around the islets 7 days after transplantation, and initiated a regenerative
process. Pancreatic β cells, and ductal cells secrete cytokines, and chemokines after damage
that recruit angiogenic cells to the pancreas. However, in this study human cells were not
detected in the murine pancreas, at day 42, after i.v. transplantation of culture-expanded
ALDHhi HPC. It is possible that i.v.-injected culture-expanded ALDHhi HPC are recruited
to the damaged islets at early time points, surround these damaged islets and secrete factors
that stimulate islet regeneration. Due to the unfavourable environment of the pancreas,
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culture-expanded ALDHhi HPC may undergo apoptosis, or migrate away from the pancreas
before day 42. IPan transplantation of culture-expanded ALDHhi HPC may further increase
pancreas engraftment, and the islet regenerative response even though ALDHhi HPC may
not survive, or migrate away from the pancreas after regenerative programs are initiated.
This study shows that it is only primitive ALDHhi HPC that stimulates endogenous islet
regeneration. Currently, researchers are attempting to develop protocols aimed at
efficiently expanding primitive HPC, and limiting unwanted cellular differentiation during
ex vivo expansion.22,52–55 For instance, Boitano et al56 have found that StemRegenin1
(SR1)-an aryl hydrocardon receptor antagonist-promotes the expansion of human
hematopoietic stem and progenitor cells. When added to serum free media supplemented
with hematopoietic growth factors this compound increased the number of primitive
CD34+ cells by 73-fold, when compared to cells cultured with only growth factors. In
addition, the expanded CD34+ cells retain both their multilineage, and long-term
engraftment potential. Hence, small molecules such as SR1 may be used in future
experiments to increase the number of HPC available for the treatment of diabetic patients.
In Summary, these studies provide proof-of-concept that ALDHhi UCB cells can be
expanded under clinically applicable hematopoietic culture conditions, and it is only the
culture-expanded primitive progenitor population (ALDHhi HPC) that retains islet
regenerative function, after transplantation in vivo. Thus, optimization of ex vivo expansion
strategies, and reselection of primitive cells using ALDH activity, may potentially lead to
the development of a cell based therapy to treat diabetes using culture-expanded allogeneic
UCB. Further elucidation of the mechanism by which progenitor cells stimulate islet
regeneration is also required to maximize islet regenerative therapies to treat diabetic
patients.
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3.1 Summary
The primary objective of this research, was to determine whether expanded UCB ALDHhi
cells could stimulate endogenous islet regeneration after transplantation into STZNOD/SCID mice. UCB ALDHhi cells were cultured for 6 days under hematopoietic serumfree culture conditions containing the obligate growth factors, SCF, TPO, and FLT-3L.
Maximal total cell expansion (53.5 ± 9.0-fold) was observed after 9 days of ex vivo culture,
however, as culture time proceeded the frequency of cells retaining high ALDH activity
and primitive cell surface phenotype (CD34, CD133) was diminished. Thus, the highest
total number of ALDHhi HPC was observed after 6 days of ex vivo expansion, resulting in
a 3.09 ± 1.1-fold expansion of total ALDHhi cells. Due to these consistent expansion
kinetics, the total HPC population was categorized into Bulk HPC, ALDHlo HPC, and
ALDHhi HPC subsets. The ALDHhi HPC subset was highly enriched for primitive
progenitor cell surface marker expression (CD34+/CD38-, CD34+/CD133+), and retained
multipotent colony forming capacity in clonal methylcellulose colony forming assays in
vitro. Thus, we characterized the islet regenerative properties using day 6 culture-expanded
HPC subpopulations purified using low versus high ALDH activity.
We have previously shown that freshly isolated UCB-derived ALDHhi cells could reduce
hyperglycemia after transplantation into STZ-NOD/SCID mice.1 In order to address
whether culture-expanded HPC, derived from ALDHhi UCB cells retained the capacity to
reduced hyperglycemia, STZ-NOD/SCID hyperglycemic mice were transplanted with
Bulk, ALDHlo or ALDHhi HPC. Mice transplanted with culture-expanded Bulk HPC or
ALDHlo HPC remained severely hyperglycemic. Interestingly, transplantation of ALDHhi
HPC consistently reduced hyperglycemia via increased islet size, and islet vascularization
upon post-mortem histochemical analyses. ALDHhi HPC transplant recipients had a
significant increase in total β cell mass, increased islet-specific proliferation, and showed
improved response to glucose bolus injection in glucose tolerance tests. Furthermore, the
culture-expanded ALDHhi HPC sub-population highly expressed pro-angiogenic
transcripts by Affymetrix microarray, compared to the more differentiated ALDHlo HPC
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subset. These findings suggest that HPC retaining high ALDH activity mediated the
recovery from hyperglycemia, by stimulating an islet proliferative and islet vascularization.

3.2 The HPC Lineage of ALDHhi UCB Progenitor Cells
Expanded Efficiently in Culture.
The HPC lineage of UCB ALDHhi cells was highly proliferative in culture. We achieved a
total cell expansion of 2.3-fold, 20.7-fold, and 53.5-fold after 3, 6, and 9 days of culture,
respectively. Culturing UCB-derived progenitor cells with hematopoietic cytokines results
in a significant expansion in committed progenitor cells, with only a minimal expansion of
primitive progenitor cells.2,3 Also, prolonged culture of UCB-derived progenitor cells
under serum-free hematopoietic culture conditions, results in unwanted cellular
differentiation. For instance, Bhatia et al.3 showed that, UCB-derived CD34+ cells
expanded by 4-fold after 4 days of culture. These cells still expressed a primitive progenitor
phenotype (CD34+/CD38-), and retained primitive SCID repopulating cells (SRC).
Whereas, 9 days of culture resulted in an 8-fold expansion of total cells, but contained no
CD34+/CD38- primitive progenitor cells, and loss of SRC function. We used relative
ALDH activity to distinguish primitive hematopoietic progenitor cells, from more
differentiated or committed progenitor cells. Similar to Bhatia et al., we found that the
frequency of primitive progenitor cells declined as culture progressed.
Furthermore, maturing progenitor cells in culture have been shown to secrete inhibitory
factors such as TGF-β that limit the proliferation and expansion of more primitive
progenitor cells.2,4 The TGF-β superfamily are pleotropic factors that regulate somatic
tissue development, and regeneration.5 When TGF-β1 was added to liquid hematopoietic
cultures it inhibited the proliferation of the primitive CD34+/CD38- cells, while stimulating
the proliferation of the more mature CD34+/CD38+ cells.6 Studies investigating the
mechanism by which TGF-β1 limits primitive progenitor cell expansion have shown that,
TGF-β1 modulates CD-117 (c-kit receptor, binds SCF), TPO receptor, and FLT-3L
receptor on primitive progenitor cells, thereby making them less responsive to these
important supplemental factors ex vivo.7–9. Due to the accumulation of inhibitory soluble
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factors in primary stem cell cultures, we first needed to determine the time point that
yielded the highest number of primitive and presumably islet regenerative ALDHhi HPC.
We found that 6 days of ex vivo expansion yielded the highest number of ALDHhi,
ALDHhi/CD34+, and ALDHhi/CD133+ HPC. Thus, we further characterized the
multipotent colony forming capacity in vitro and islet regenerative properties after i.v.transplantation using 6 day culture-expanded HPC subpopulations.

3.3 Transplanted ALDHhi HPC Stimulated Islet
Angiogenesis
The endocrine pancreas in highly vascularized, it has 5-7 times more capillaries that the
surrounding exocrine pancreas tissue.10 These islet capillary network provides glucose
sensing pancreatic islets with nutrients, and oxygen.11 In addition, the islet capillary
network is essential for optimal islet function. A dense islet capillary network is required
for β cells to optimally sense blood glucose levels, and the fenestrations in the islet capillary
endothelium is the most efficient way for insulin secreted by β cells to enter the systemic
circulation.12 Furthermore, the islet capillary endothelium also supports β cell turnover. In
an in vitro system, purified islet endothelial cells stimulated β cell proliferation primarily
via the secretion of HGF.13 During pregnancy pancreatic β cells can undergo enhanced
turnover. In vivo experiments, in pregnant rats showed that HGF levels were highly
expressed in the islet capillary endothelium during peak stimulation of β cell
proliferation.13 Another study showed that, laminins expressed on the basement membrane
of the islet endothelium, binds to β1 integrin on β cells to stimulate β cell proliferation.14
Collectively, these studies suggest that endothelial-endocrine axis plays an important role
in supporting β cell function, and β cell turnover.
Previously, we have shown that freshly isolated UCB cells with high ALDH activity
contains pro-angiogenic progenitor cells that improved the perfusion of the ischemic limb,
following transplantation into immunodeficient mice with acute hind-limb ischemia
induced by femoral artery ligation.15 Freshly isolated UCB ALDHhi cells did not integrate
into the murine vasculature, instead UCB ALDHhi cells homed selectively to areas of
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inflammation in the ischemic limb, and stimulated endogenous murine capillary
regeneration.15 Here we show that a subset of the culture-expanded progeny, ALDHhi HPC,
significantly enhanced islet-specific capillary density in the STZ-treated mouse pancreas.
VEGF is highly expressed in β cells, and is not expressed in extra-islet tissues.11,12,16,17
Increased vascularization was specific to the islets, rather than extra-islet pancreatic tissue,
suggesting that the VEGF is required for culture-expanded ALDHhi HPC to support an islet
specific vascularization program, in the pancreas of STZ-NOD/SCID diabetic mice.
Interestingly increased CD31+ capillary density was associated with an increased islet size
and, islet cell proliferation, resulting in increased total β cell mass, and improved islet
function. Thus, our data suggest that the transplantation of ALDHhi HPC improves islet
function in STZ-NOD/SCID mice by re-establishing the endothelial-endocrine axis (Figure
3.1).
Intra-Pancreatic transplantation of freshly isolated UCB cells with high ALDH activity
stimulated islet revascularization, and β cell proliferation in STZ-NOD/SCID mice, despite
remarkably low level of engraftment (0.09 ± 0.03%, n=6 mice) of freshly isolated ALDHhi
UCB cells in the pancreas, at day 42.1 However, iPan transplantation of ALDHhi UCB cells
increased early recruitment of islet regenerative cells immediately surrounding
regenerating islets at 7 days post transplantation. Presumably, many of these injected cells
were lost by 1 month post-transplantation. Interestingly, iPan transplantation of freshly
isolated UCB ALDHhi cells was more effective at improving systemic glycemia, compared
to i.v. transplantation for UCB ALDHhi cells. Thus, we postulated that increased exposure
of recovering islets to UCB ALDHhi cell secreted stimuli augmented a natural or
endogenous islet regenerative process. Pancreatic β cells and ductal cells are known to
secrete angiogenic growth factors such as vascular endothelial growth factor (VEGF), and
chemokines such as stromal derived factor 1 (SDF-1), that recruit a pro-angiogenic cells
specifically to STZ-damaged islets. In these studies human cells were not detected in the
murine pancreas, at day 42, after i.v.-transplantation of culture-expanded ALDHhi HPC.
Although early time course recruitment experiments have not yet been performed using
expanded HPC subsets, we speculate i.v.-injected culture-expanded ALDHhi HPC were
recruited to the damaged islets at early time points, surround these damaged islets and
secrete factors that stimulate islet regeneration. However, due to the unfavourable
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environment of the pancreas culture-expanded ALDHhi HPC may undergo apoptosis, or
migrate away from the pancreas before day 42 leaving the regenerative effects observed
appear short-term and not sustained. Thus, iPan transplantation of culture-expanded
ALDHhi HPC may further increase early pancreas engraftment, and may augment the islet
regenerative response via the initiation of islet regenerative programs. These important
experiments are planned for future studies

3.4 ALDHhi HPC Secrete Cytokines Involved in
Angiogenesis
The mRNA levels of the secreted proteins Semaphorin 4A (SEMA4A), Angiopoietin 2
(ANGPT2), and Milk Fat Globule-EGF factor 8 (MFG-E8) were higher in cultureexpanded ALDHhi HPC compared to ALDHlo HPC. The proteins encoded by these
transcripts are all involved in supporting vascular endothelial growth factor-A (VEGFA)
mediated angiogenesis. MFG-E8 also known as lactadherin has been shown to interact with
αvβ3 integrins on endothelial cells, and cooperates with VEGF signaling to activate a potent
pro-angiogenic pathway.18 Interestingly, in the hind-limb ischemic model injection of antiMFG-E8 blocked VEGFA induced angiogenesis.18 The transcript of ANGPT2 was also up
regulated in culture-expanded ALDHhi HPC. Studies have shown that, ANGPT2 is a
complex regulator of vascular remodelling that supports both vessel sprouting and vessel
regression. In the setting of angiogenic sprouting ANGPT2 is rapidly induced with VEGF,
whereas in the setting of vascular regression, ANGPT2 is induced in the absence of
VEGF.19–24 Studies in mice lacking ANGPT2 shows that, ANGPT2 is essential for
postnatal vascular remodeling of the eye. The retina of post natal mice lacking ANGPT2,
was devoid of peripheral vessels, and had minimal central vasculature.25 Pancreatic β cells
express high levels of VEGF.12,16,17 It is plausible that MFG-E8, and ANGPT2 secreted by
ALDHhi HPC stimulate islet vascularization, by supporting a VEGF dependent angiogenic
program.
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Figure 3.1 Working Model. Schematic of the proposed mechanism by which ALDHhi
HPC improves islet function. Our data suggest that transplanted ALDHhi HPC surround
damaged islets and secrete factors such as SEMA4A, ANGPT2, and MFGE8 that supports
islet angiogenesis, to re-establishing the endothelial-endocrine axis. HGF secreted by
endothelial cells, or laminins expressed on the basement membrane of endothelial cells
support β cell proliferation, which results in an increased islet size, and β cell mass.
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Finally, the transcript of SEMA4A was up-regulated in culture-expanded ALDHhi HPC.
SEMA4A has been shown to act on PlexinD1 receptors, to stimulate the release of VEGFA
from macrophages.26 The VEGFA subsequently secreted from macrophages, after SEM4A
stimulation exerted a pro-angiogenic effect on endothelial cells in vitro, by activating the
P13/AKT pathway in endothelial cells. Furthermore, the VEGFA produced by accessory
macrophages stimulated angiogenesis in the in vivo chorioallantonic membrane (CAM)
assay. Interestingly, although the NOD/SCID is completely depleted of T and Blymphocyte activity, the NOD/SCID does retain residual macrophage and NK-cells of the
innate immune system Thus, residual mouse macrophages may be recruited to the pancreas
after STZ-induced islet injury in our model and may act as accessory cells in the islet
regenerative process.27 Adoptive transfer of M2 macrophages have been shown to protect
NOD mice from developing diabetes, by homing to the inflamed pancreas and secreting
anti-inflammatory cytokines.27 SEM4A produced by ALDHhi cells may act on the
PlexinD1 receptors on these macrophages to stimulate VEGFA release, which
subsequently supports angiogenesis in regenerating islets of STZ-treated diabetic mice.
Collectively, these data suggests that the pro-angiogenic microenvironment established in
the pancreas of STZ-NOD/SCID diabetic mice after the transplantation of ALDHhi HPC
may be beneficial to islet regeneration through the activity of murine macrophage
intermediates.

3.5 Increasing the Number of Primitive CultureExpanded HPC for a Cell Based Therapy to Treat
Diabetes
In this study we show that culture-expanded HPC retaining a primitive progenitor
phenotype (ALDHhi HPC) stimulate endogenous islet regeneration in STZ-NOD/SCID
diabetic mice. Conversely, more differentiated ALDHlo HPC or even unsorted Bulk HPC
could not stimulate similar regenerative processes in situ. For hematopoietic
transplantation applications using UCB cells, researchers have attempted to increase the
number primitive HPC during the ex vivo expansion of the HPC lineage. Recent success
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has been achieved by, adding small molecules to hematopoietic culture conditions, and
expanding UCB progenitor cells in a bioreactor using a batch fed system.28–34
For instance, Boitano et al.29 have found that StemRegenin1 (SR1)-an aryl hydrocardon
receptor antagonist-promotes the overall expansion of human HPC. When added to serum
free media supplemented with hematopoietic growth factors this compound increased the
number of primitive CD34+ cells by 73-fold, when compared to cells cultured with growth
factors alone (basal culture conditions). Importantly, the number of SRC that retain both
multilineage and long-term engraftment potential, increased by 8-fold compared to basal
culture conditions.
ALDH is highly expressed in HPC, and is a critical enzyme in the biosynthesis of RA. The
addition of RA to hematopoietic culture (SCF, FLT3L, TPO), resulted in HPC
differentiation.32 Chute et al.32 found that inhibiting ALDH with the small molecule DEAB
in hematopoietic culture (SCF, FLT-3L, TPO) decreased RA signaling in HPC.
Furthermore, when DEAB was added to hematopoietic the number of primitive SRC
increased by 6-fold compared to cells cultured in basal hematopoietic culture conditions.
Csaszar et al.28 developed an automated controlled fed-batch dilution approach to expand
UCB progenitor cells. UCB cells were cultured in hematopoietic conditions in a bioreactor,
and new media was added at a constant flow rate to the hematopoietic culture. Using this
approach the factors that inhibit the growth of primitive progenitor cells such as TGF-β are
constantly diluted and removed from the culture microenvironment. As a result, the number
of CD34+ cells was increased by 80-fold, when compared to UCB cells expanded under
basal (non-batch fed) conditions. In addition, the number of SRC increased by 11-fold
compared to control conditions. Thus, the number of primitive HPC available to treat
diabetes using the stimulation of endogenous islet regeneration could be increased in the
future by adding small molecules to hematopoietic culture conditions or by expanding
UCB ALDHhi progenitor cells using a batch-fed a bioreactor system.
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3.6 Clinical Implications
Our data outlines a clinically applicable regenerative approach for the treatment of
diabetes. Allogeneic human UCB progenitor cells can be isolated in a clinically relevant
manner using ALDH activity, and the HPC lineage of the ALDHhi UCB cells can be
expanded without serum or xenobiotic agents in clinically applicable fashion. High ALDH
activity can subsequently be used to re-select cells with islet regenerative properties after
culture, and prior to transplantation. Furthermore, the number of primitive HPC with islet
regenerative properties can be further increased by adding clinically applicable small
molecules to hematopoietic cultures, or by expanding hematopoietic cells using a batchfed bioreactor system.
In order for culture=expanded ALDHhi HPC to be a plausible therapy for type-1 diabetes,
the issue of continued autoimmune destruction of regenerated β cells must be addressed.
Solvason et al.35 demonstrated that a plasmid DNA vaccine encoding mouse proinsulin II
(BHT-3021) reduced the incidence of diabetes, when administered into NOD mice both
before the onset of hyperglycemia (prophylactically), and after the onset of hyperglycemia
(therapeutically). BHT-3021 recently completed phase I clinical trials in type-1 diabetic
patients diagnosed within the past 5 years.36 No adverse events were reported in subjected
treated with BHT-3021. In fact, the subjects administered with BHT-3021 demonstrated
improved c-peptide level compared to placebo treated subjects even without the stimulation
of endogenous islet regenerative processes. In addition, the frequency of proinsulin reactive
CD8+ T-cells declined in BHT-3021 treated subjects. This trial clearly shows that, BHT3021 reduces frequency of CD8+ T cells reactive to proinsulin, while preserving c-peptide
levels over the course of dosing. However, the β cell mass of type 1 diabetic patients is
already reduced by 70-80% at the time of diagnosis.37 Thus, ALDHhi HPC that increases β
cell mass and endogenous glucose secretion, together with BHT-3021 that prevents further
β cell deletion and preserves β cell function may represent a highly rationalized potential
strategy to treat type 1 diabetes.
As mentioned earlier, the Medalist study revealed that diabetic patients with long standing
diabetes demonstrate residual β cell function.38 Thus, culture-expanded ALDHhi HPC from
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widely accessible UCB samples can be potentially utilized to stimulate endogenous β cell
regeneration in diabetic patients with long standing diabetes.
Transplantation of culture-expanded ALDHhi HPC may also represent a potential strategy
for the therapy for type 2 diabetic patients, who have a decreased β cell mass, and insulin
resistance at advanced stages of the disease.39 Although the issue of insulin resistance in
these patients will still need to be addressed by diet, exercise, and hypoglycemic agents,
culture-expanded ALDHhi HPC can aid in restoring β cell mass, and increase the insulin
available to meet metabolic demand, essentially “tipping the balance” in favour of islet
regeneration versus metabolic destruction in end-stage (insulin-dependent). We are
currently generating preclinical xenotransplantation models of type 2 diabetes using the
longer-lived NOD/SCID gamma (NSG) xenotransplantation model combined with high fat
diet and low dose STZ monotherapy
Our study has several limitation that needs to be addressed before our findings can be
applied to the clinic. Firstly, the glucometer we used for glucose tolerance testing was only
able to detect a maximum glucose concentration of 33mmol/L. Therefore, to better
characterize the glucose tolerance of mice transplanted with ALDHlo HPC, and ALDHhi
HPC a glucometer with a higher range is required as readings in the mice were maximal
after the injection of a glucose bolus. Alternatively, mouse blood samples could be diluted
prior to glucose measurement to ensure that readings were within the range of
quantification by the glucometer, resulting in more accurate glucose tolerance
measurements. Also, type 1 diabetes involves the auto-immune destruction of β cells,
whereas our diabetic mouse model involves the chemical destruction of β cells to induce
hyperglycemia in immunodeficient NOD/SCID mice. Therefore, β cell regeneration is
being studied in a model free of any autoimmune attack on islets. In addition, type 2
diabetes is a metabolic disease usually associated with obesity. Our NOD/SCID diabetic
mouse model only depicts the hyperglycemia of type 2 diabetes, thus islet regeneration is
studied in the absence of many inflammatory cytokines and metabolites associated with
obesity. Finally, studying the islet regenerative properties of human cells is important,
because these cells may eventually be used in human clinical trials. However, due to
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species incompatibilities, transplantation of human progenitor cells into a mouse model
may not fully recapitulate the regenerative capacity of human progenitor cells.

3.7 Future Directions
BHT-3201 preserves β cell function, while ALDHhi HPC stimulates endogenous islet
regeneration. Studies could be performed in NOD mice, in order to determine if these
therapeutic agents can work in combination to treat type 1 diabetes. In order to determine
if ALDHhi HPC can stimulate endogenous islet regeneration in type 2 diabetic milieu,
ALDHhi HPC could be transplanted into NSG type 2 diabetic mouse model. After
transplantation islet function, β cell mass, and islet vascular density needs to be assessed.
By microarray analysis of ALDHhi HPC and ALDHlo HPC sub-populations this study
identified MFG-E8, SEMA4A, and ANGPT2 to be potentially involved in stimulating islet
specific angiogenesis. To further gain insight into the islet regenerative niche these
microarray hits needs be confirmed by performing ELISA on the supernatants or by
western blot on cell lysates from culture-expanded ALDHhi HPC and ALDHlo HPC subsets.
In order determine if these secreted proteins are directly involved in islet revascularization,
ALDHhi HPC needs to be intravenously transplanted with either MFG-E8, or SEMA4A,
or ANGPT2 antibodies individually or with a combination of these antibodies, and islet
function, β cell mass, and islet vascular density must be assessed. Further understanding
the regenerative niche will aid in the optimization of a cellular regenerative therapy using
expanded HPC therapy to promote islet function as a part of a multidisciplinary rational
approach to treat both type 1 or type 2 diabetes.
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publication is 15%. As of now this manuscript is 98% complete.
Patel P, Brooks C, Seneviratne A, Hess DA and Séguin CA. Investigating
Microenvironmental Regulation of Human Chordoma Cell Behaviour.
My role in this project is to design and perform experiments to characterize the phenotype
of human chordoma cells cultured in hypoxic or normoxic conditions. Overall, my
contribution to the team effort for this publication is 5%. As of now this manuscript is 80%
complete.

Section 4: Presentations
Ayesh Seneviratne, Gillian I. Bell, Stephen Sherman, David M. Putman, David A. Hess. A
Sub-Population of Expanded Hematopoietic Progenitor Cells that Retain High Aldehyde
Dehydrogenase Activity Improves Islet Function by Stimulating Endogenous Islet
Regeneration and Vascularization. Accepted for poster presentation by the Molecular
Medicine Group at the Robarts Research Institute for presentation at the 1st annual
Robarts Research Retreat, Bellamere Winery, June 9, 2014.
Ayesh Seneviratne, Gillian I. Bell, Stephen Sherman, David M. Putman, David A. Hess. A
Sub-Population of Expanded Hematopoietic Progenitor Cells that Retain High Aldehyde
Dehydrogenase Activity Improves Islet Function by Stimulating Endogenous Islet
Regeneration and Vascularization. The Collaborative Graduate Program in
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Developmental Biology 6th annual Developmental Biology research day, Civic Garden
complex, May 30, 2014.
Ayesh Seneviratne, Gillian I. Bell, Stephen Sherman, David M. Putman, David A. Hess. A
Sub-Population of Expanded Hematopoietic Progenitor Cells that Retain High Aldehyde
Dehydrogenase Activity Improves Islet Function by Stimulating Endogenous Islet
Regeneration and Vascularization. Schulich School of Medicine and Dentistry London
Health research day, London Convention Centre, March 18, 2014.
Ayesh Seneviratne, Gillian I. Bell, Stephen Sherman, David M. Putman, David A. Hess. A
Sub-Population of Expanded Hematopoietic Progenitor Cells that Retain High Aldehyde
Dehydrogenase Demonstrates Islet Regenerative Properties. Schulich School of Medicine
and Dentistry 4th annual Diabetes research day, St. Joseph’s Hospital, November 12, 2013.
Ayesh Seneviratne, Gillian I. Bell, Stephen Sherman, David M. Putman, David A. Hess. A
Sub-Population of Expanded Hematopoietic Progenitor Cells that Retain High Aldehyde
Dehydrogenase Demonstrates Islet Regenerative Properties. Deparment of Physiology and
Pharmacology Gowdey research day, Western University, November 4, 2013. 1st place
award Recipient for the best poster.
Ayesh Seneviratne, Gillian I. Bell, Stephen Sherman, David M. Putman, David A. Hess. A
Sub-Population of Expanded Hematopoietic Progenitor Cells that Retain High Aldehyde
Dehydrogenase Improves Islet Function. The Collaborative Graduate Program in
Developmental Biology 5th annual Developmental Biology research day, Civic Garden
complex, May 30, 2013
Ayesh Seneviratne, Gillian I. Bell, Heather C. Broughton, David A. Hess. The Phenotype and
Islet Regenerative Functions of ex vivo Expanded Hematopoietic Progenitor Cells. Schulich
School of Medicine and Dentistry London Health research day, London Convention
Centre, March 19, 2013.
Ayesh Seneviratne, Gillian I. Bell, Heather C. Broughton, David A. Hess. The Phenotype and
Islet Regenerative Functions of ex vivo Expanded Hematopoietic Progenitor Cells. Schulich
School of Medicine and Dentistry 3rd annual diabetes research day, St. Joseph’s Hospital,
November 13, 2012. 2nd place award Recipient for the best poster.
Ayesh Seneviratne, Gillian I. Bell, David M. Putman, David A. Hess. The Phenotype and Islet
Regenerative Functions of ex vivo Expanded Hematopoietic Progenitor Cells. Deparment of
Physiology and Pharmacology Stevenson research day, Western University, November 6,
2012. 2nd place award Recipient for the best poster.

Ayesh Seneviratne, Gillian I. Bell, Heather C. Broughton, David A. Hess. The Effect of
Transplanted Human Hematopoietic Progenitor Lineage on β cell Proliferation and Islet
Regeneration. Deparment of Physiology and Pharmacology annual 4th year thesis
student research day, Western University, April 2, 2012.
Ayesh Seneviratne, Maria Cusimano, Mahadeo A Sukhai, Bozena Livak, Angela
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Rutledge, Rose Hurren, Paul Spagnuolo, Aaron D. Schimmer. Lysosomal Disruption
Selectively Targets Leukemia Cells Through a Mechanism Related to Increased ROS
Production. Deparment of Physiology and Pharmacology Gowdey research day,
Western University, November 8, 2011.
Ayesh Seneviratne, Maria Cusimano, Mahadeo A Sukhai, Bozena Livak, Angela
Rutledge, Rose Hurren, Paul Spagnuolo, Aaron D. Schimmer. Lysosomal Disruption
Selectively Targets Leukemia Cells Through a Mechanism Related to Increased ROS
Production. Department of Medical Biophysics summer student presentation,
University of Toronto, August 18, 2011.
Ayesh Seneviratne, Mahadeo A. Sukhai, Joyce Sun, Xiaoming Li, Aaron D. Schimmer.
Aberrant Expression of Toll-Like Receptors in Acute Myelogenous Leukemia.
Department of Medical Biophysics summer student presentation, University of
Toronto, August 13, 2010.
Ayesh Seneviratne, Mahadeo A. Sukhai, Joyce Sun, Xiaoming Li, Aaron D. Schimmer.
Aberrant Expression of Toll-Like Receptors in Acute Myelogenous Leukemia
CIHR Biological Therapeutics summer student presentation, July 26, 2010.

Section 5: Teaching Experience
September 2012-Present: Teaching Assistant Physiology 3130Y, Western University
 Responsible for facilitating the pre-lab tutorials, post lab tutorials, and helping
students to complete their lab.
September 2009-May 2010: Tutor for Frontier College, an institution that helps
underprivileged individuals with their academics.
 Helped children from ages 8-13 with reading and assignments
Sept 2007-June 2008: Peer Tutor- Applewood Heights Secondary School,
Mississauga Ontario.
 Mentored and guided grade 9 and 10 students to achieve better academic
result
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Section 6: Supervisory and Mentorship Experience
September 2013-Present

May 2013-August 2013

Mr. Tyler Cooper, 4th year Research
Student, Department of Biology,
University of Western Ontario, London,
Ontario. Project Title: The Phenotype
and Colony Forming Capacity of
Hematopoietic Progenitor cells
Expanded by the Modulation of the
Retinoic Acid Pathway.
Mr. Stephen Sherman, Summer Student
Robarts Research Institute, London,
Ontario

Section 7: Technical Experience




Proficient in vivo procedures such as: 1) intravenous transplantation,
intrapancreatic transplantation procedures; 2) subcutaneous, intramuscular, and
intraperitoneal injection procedures; 3) Intravenous, and intracardiac blood
collection procedures.
Proficient in vitro assays such as: cell imunotyping using flow cytometry, tissue
culture, transfection methodologies, immunohistochemistry, colony formation
unit assay

Section 8: Academic Accomplishments and Awards
Master’s
Studentships:
 Recipient, Ontario graduate scholarship (2013-2014; $15,000)
 Recipient, Ontario Graduate Scholarship (2012-2013; $15,000).
Travel Awards:
 Recipient, Stem Cell Network travel award (2013)
 Recipient, Ontario Stem Cell Initiative travel award (2013; $ 1,000)
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Poster Awards:




Recipient, 1st place award Recipient in the Category of Endocrinology and
Reproductive Physiology at the Deparment of Physiology and Pharmacology
Gowdey research day, Western University (November 4, 2013; $250).
Recipient, 2nd place award for the best poster at the Schulich School of Medicine and
Dentistry annual diabetes research day, St. Joseph’s Hospital (November 13, 2012;
$200).
Recipient, 2nd place award Recipient in the Category of Endocrinology and
Reproductive Physiology at the Deparment of Physiology and Pharmacology
Stevenson research day, Western University (November 6, 2012; $100).

Undergraduate
Studentships:
 Recipient, University of Toronto Summer Undergraduate Studentship Award
(2011; $2400).
 Recipient, University of Toronto Summer Undergraduate Studentship Award
(2010; $2400).
 Summer Studentship, CIHR strategic training program in biological therapeutics
(2010).
Scholarships:
 Recipient, Richard Ivey Foundation International Exchange Scholarship
(2010/11; $5,000).
 Queen Elizabeth Scholarship (2008-2012; $3,500/yr).
 University of Western Ontario Scholarship of Excellence (2008/09; $2000).
Academic Accomplishments:
 University of Western Ontario Dean’s Honours’ list (2008-2012).
 University of Western Ontario Scholar (2008-2012).
Secondary School
 Ontario Scholar (2007-2008)
 Applewood Heights Secondary School Honors list (2006-2008)
 Proficiency, Introduction to Anthropology, Sociology, and Psychology (2006/07)

